<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:voc="urn:hl7-org:v3/voc" xmlns="urn:hl7-org:v3" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="410fbffa-bcb8-e68d-a46d-3074c96a67a7"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use PAROXETINE TABLETS safely and effectively. See full prescribing information for PAROXETINE TABLETS. PAROXETINE TABLETS, for oral use<br/> Initial U.S. Approval: 1992<br/>
      <br/>
      <br/>
      <br/>
      <br/>
      <br/>
      <br/>
      <br/>
   </title>
   <effectiveTime value="20250410"/>
   <setId root="08320ea3-8f93-6f04-5d1c-f69af3eb5a81"/>
   <versionNumber value="24"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="845263701" root="1.3.6.1.4.1.519.1"/>
            <name>Apotex Corp.</name>
            <assignedEntity>
               <assignedOrganization>
                  <id extension="209429182" root="1.3.6.1.4.1.519.1"/>
                  <name>Apotex Inc.</name>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="3fe6b78e-08c7-e0f1-f1a6-4802d232ceb6"/>
               <code code="48780-1" displayName="SPL PRODUCT DATA ELEMENTS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <effectiveTime value="20250410"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="60505-0097" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>PAROXETINE</name>
                        <formCode code="C42931" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, FILM COATED"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>paroxetine hydrochloride</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="10"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="3I3T11UD2S" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PAROXETINE HYDROCHLORIDE ANHYDROUS</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="41VRH5220H" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>Paroxetine</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3SY5LH9PMK" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ANHYDROUS LACTOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="RFW2ET671P" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROXYPROPYL CELLULOSE (1600000 WAMW)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="Q662QK8M3B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL 8000 </name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5856J3G2A2" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM STARCH GLYCOLATE TYPE A POTATO</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="30"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69" code="60505-0097-1"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20030908"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="90"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69" code="60505-0097-9"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="completed"/>
                                 <effectiveTime>
                                    <low value="20030908"/>
                                    <high value="20210602"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="100"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69" code="60505-0097-2"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20030908"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="1000"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69" code="60505-0097-4"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20030908"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="18000"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69" code="60505-0097-7"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="completed"/>
                                 <effectiveTime>
                                    <low value="20030908"/>
                                    <high value="20210602"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="10"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="10"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code codeSystem="2.16.840.1.113883.6.69" code="60505-0097-5"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="completed"/>
                                       <effectiveTime>
                                          <low value="20030908"/>
                                          <high value="20210602"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48345" displayName="OVAL" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="2" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" displayName="WHITE" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="9" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">APO;097</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20030908"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA075356" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="60505-0083" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>PAROXETINE</name>
                        <formCode code="C42931" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, FILM COATED"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>paroxetine hydrochloride</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3SY5LH9PMK" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ANHYDROUS LACTOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="RFW2ET671P" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROXYPROPYL CELLULOSE (1600000 WAMW)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="Q662QK8M3B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL 8000 </name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5856J3G2A2" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM STARCH GLYCOLATE TYPE A POTATO</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="20"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="3I3T11UD2S" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PAROXETINE HYDROCHLORIDE ANHYDROUS</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="41VRH5220H" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>Paroxetine</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="30"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69" code="60505-0083-1"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20030908"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="90"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69" code="60505-0083-9"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="completed"/>
                                 <effectiveTime>
                                    <low value="20030908"/>
                                    <high value="20210206"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="100"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69" code="60505-0083-2"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20030908"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="1000"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69" code="60505-0083-4"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20030908"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="12500"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69" code="60505-0083-0"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="completed"/>
                                 <effectiveTime>
                                    <low value="20030908"/>
                                    <high value="20120630"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="10"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="10"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code codeSystem="2.16.840.1.113883.6.69" code="60505-0083-5"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="completed"/>
                                       <effectiveTime>
                                          <low value="20030908"/>
                                          <high value="20210602"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48345" displayName="OVAL" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="2" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" displayName="WHITE" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="11" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">APO;083</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20030908"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA075356" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="60505-0084" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>PAROXETINE</name>
                        <formCode code="C42931" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, FILM COATED"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>paroxetine hydrochloride</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3SY5LH9PMK" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ANHYDROUS LACTOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="RFW2ET671P" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROXYPROPYL CELLULOSE (1600000 WAMW)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="Q662QK8M3B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL 8000 </name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5856J3G2A2" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM STARCH GLYCOLATE TYPE A POTATO</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="30"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="3I3T11UD2S" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PAROXETINE HYDROCHLORIDE ANHYDROUS</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="41VRH5220H" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>Paroxetine</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="30"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69" code="60505-0084-1"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20030908"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="90"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69" code="60505-0084-9"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="completed"/>
                                 <effectiveTime>
                                    <low value="20030908"/>
                                    <high value="20210602"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="100"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69" code="60505-0084-2"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20030908"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="1000"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69" code="60505-0084-4"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20030908"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="10"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="10"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code codeSystem="2.16.840.1.113883.6.69" code="60505-0084-5"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="completed"/>
                                       <effectiveTime>
                                          <low value="20030908"/>
                                          <high value="20210602"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48345" displayName="OVAL" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" displayName="WHITE" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="13" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">APO;084</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20030908"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA075356" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="60505-0101" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>PAROXETINE</name>
                        <formCode code="C42931" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, FILM COATED"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>paroxetine hydrochloride</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3SY5LH9PMK" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ANHYDROUS LACTOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="RFW2ET671P" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROXYPROPYL CELLULOSE (1600000 WAMW)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="Q662QK8M3B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL 8000 </name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5856J3G2A2" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM STARCH GLYCOLATE TYPE A POTATO</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="40"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="3I3T11UD2S" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PAROXETINE HYDROCHLORIDE ANHYDROUS</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="41VRH5220H" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>Paroxetine</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="30"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69" code="60505-0101-1"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20030908"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="90"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69" code="60505-0101-9"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="completed"/>
                                 <effectiveTime>
                                    <low value="20030908"/>
                                    <high value="20210602"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="100"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69" code="60505-0101-2"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20030908"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="1000"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69" code="60505-0101-4"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20030908"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="10"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="10"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code codeSystem="2.16.840.1.113883.6.69" code="60505-0101-5"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="completed"/>
                                       <effectiveTime>
                                          <low value="20030908"/>
                                          <high value="20210602"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="7000"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69" code="60505-0101-7"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="completed"/>
                                 <effectiveTime>
                                    <low value="20030908"/>
                                    <high value="20210602"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48345" displayName="OVAL" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" displayName="WHITE" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="14" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">APO;101</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20030908"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA075356" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <component>
                  <section>
                     <id root="011658b7-851d-60c5-52ba-806688152409"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <effectiveTime value="20101214"/>
                     <component>
                        <observationMedia ID="MM609920840716">
                           <text>10mg-30s-btl.jpg</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="10mg-30s-btl.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="MM69655499239">
                           <text>20mg-30s-btl.jpg</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="20mg-30s-btl.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="MM206243356011">
                           <text>30mg-30s-btl.jpg</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="30mg-30s-btl.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="MM460627999389">
                           <text>40mg-30s-btl.jpg</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="40mg-30s-btl.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="MM690184452102">
                           <text>structure</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="structure.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="MM796253500334">
                           <text>figure1.jpg</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="figure1.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="MM420945102352">
                           <text>figure2.jpg</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="figure2.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="MM805103925762">
                           <text>figure3.jpg</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="figure3.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="_c6e448f7-fda9-d4bc-fedb-0c7f7e11330b">
               <id root="4c3c89fd-4441-1b4f-3484-94f7bbf07e71"/>
               <code code="34066-1" displayName="BOXED WARNING SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>WARNING: SUICIDAL THOUGHTS AND BEHAVIORS</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric andyoung adult patients in short-term studies. Closely monitor all antidepressant-treatedpatients for clinical worsening, and for emergence of suicidal thoughts and behaviors </content>
                     <content styleCode="bold italics">[seeWarnings and Precautions (<linkHtml href="#_9dff5b7a-4deb-c87c-5aa7-c4a74463c4e8">5.1</linkHtml>)]. </content>
                     <content styleCode="bold">Paroxetine tablets are not approved for use in pediatric patients </content>
                     <content styleCode="bold italics">[see Usein Specific Populations (</content>
                     <content styleCode="bold italics">
                        <linkHtml href="#_f399a731-bb7e-72b7-ef00-b849dffcc08e">8.4</linkHtml>)].</content>
                  </paragraph>
               </text>
               <effectiveTime value="20210531"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="bold">WARNING:SUICIDALTHOUGHTSANDBEHAVIORS</content>
                           <br/>
                           <content styleCode="bold italics">Seefullprescribinginformationforcompleteboxedwarning.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold italics"/>
                           <content styleCode="bold">Increased risk of suicidal thoughts and behavior in pediatric and youngadultpatientstakingantidepressants.Closelymonitorallantidepressant-treatedpatientsfor clinicalworseningandemergenceofsuicidalthoughts and behaviors. Paroxetine tablets are not approved for use in pediatricpatients.(<linkHtml href="#_9dff5b7a-4deb-c87c-5aa7-c4a74463c4e8">5.1</linkHtml>,<linkHtml href="#_f399a731-bb7e-72b7-ef00-b849dffcc08e">8.4</linkHtml>)</content>
                        </paragraph>
                        <paragraph/>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="_e9c1460c-0cde-b4c5-1ab0-2cd175714c63">
               <id root="bd805879-d734-21cc-770f-2b24111cc604"/>
               <code code="43683-2" displayName="RECENT MAJOR CHANGES SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>RECENT MAJOR CHANGES</title>
               <effectiveTime value="20250103"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Warnings and Precautions (<linkHtml href="#_25e0dbe0-a5e5-c7fc-94b2-5f1f881cec3d">5.4</linkHtml>) 11/2024</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="_BBDDC165-BCAB-D543-B1D0-83B67377679A">
               <id root="9e837bc9-6292-fd4d-2c04-53b8140173f1"/>
               <code code="34067-9" displayName="INDICATIONS &amp; USAGE SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>Paroxetine tablets areindicatedinadultsforthetreatmentof:</paragraph>
                  <list>
                     <item>Majordepressivedisorder(MDD)</item>
                     <item>Obsessivecompulsivedisorder(OCD)</item>
                     <item>Panicdisorder(PD)</item>
                     <item>Socialanxietydisorder(SAD)</item>
                     <item>Generalizedanxietydisorder(GAD)</item>
                     <item>Posttraumaticstressdisorder(PTSD)</item>
                  </list>
               </text>
               <effectiveTime value="20210531"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Paroxetine tablets is a selective serotonin reuptake inhibitor (SSRI) indicated in adults forthetreatment of (<linkHtml href="#_BBDDC165-BCAB-D543-B1D0-83B67377679A">1</linkHtml>):</paragraph>
                        <list>
                           <item>MajorDepressiveDisorder(MDD)</item>
                           <item>ObsessiveCompulsiveDisorder(OCD)</item>
                           <item>PanicDisorder(PD)</item>
                           <item>SocialAnxietyDisorder(SAD)</item>
                           <item>GeneralizedAnxietyDisorder(GAD)</item>
                           <item>PosttraumaticStressDisorder(PTSD)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="_0d37132d-cd62-5aee-932b-7b7e0c0a8bf3">
               <id root="3b56988a-ada1-4cde-dfc5-d74f3febcd0a"/>
               <code code="34068-7" displayName="DOSAGE &amp; ADMINISTRATION SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20210530"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list>
                           <item>Recommended starting and maximum daily dosage for MDD, OCD, PD,andPTSD: (<linkHtml href="#_01eaacab-2a65-d556-fdd7-b95c2fadc27c">2.2</linkHtml>)</item>
                        </list>
                        <table frame="border" rules="all">
                           <tbody>
                              <tr>
                                 <td>
                                    <content styleCode="bold">Indication</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">StartingDailyDose</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">MaximumDailyDose</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td>MDD</td>
                                 <td>20 mg</td>
                                 <td>50 mg</td>
                              </tr>
                              <tr>
                                 <td>OCD</td>
                                 <td>20mg</td>
                                 <td>60mg</td>
                              </tr>
                              <tr>
                                 <td>PD</td>
                                 <td>10mg</td>
                                 <td>60mg</td>
                              </tr>
                              <tr>
                                 <td>PTSD</td>
                                 <td>20 mg</td>
                                 <td>50 mg</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph/>
                        <list>
                           <item>RecommendedstartingdosageforSADandGADis20mg daily.(<linkHtml href="#_bb0b2899-d167-0a27-127e-24c660455c02">2.3</linkHtml>)</item>
                           <item>Elderly patients, patients with severe renal impairment or severe hepaticimpairment: Starting dosage is 10 mg daily. Maximum dosage is 40 mgdaily.(<linkHtml href="#_e67c140b-fa03-cad9-26f1-ff27becbe06b">2.4</linkHtml>)</item>
                           <item>Whendiscontinuingparoxetine tablets,reducedosagegradually.(<linkHtml href="#_7909df01-8ad6-251b-2e05-0a6f7a3a24be">2.6</linkHtml>,<linkHtml href="#_374de3a0-febe-dffe-139a-413f4ec088ca">5.7</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="_49459c49-22db-dcac-5d92-9bd600afd6df">
                     <id root="d9d2d4c6-508d-32d1-bcfb-6c82817645d0"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>  2.1 Administration Information</title>
                     <text>
                        <paragraph>Administerparoxetine tabletsasasingledailydoseinthemorning,withorwithoutfood.</paragraph>
                     </text>
                     <effectiveTime value="20210531"/>
                  </section>
               </component>
               <component>
                  <section ID="_01eaacab-2a65-d556-fdd7-b95c2fadc27c">
                     <id root="f1f78eb9-efa9-8d08-696f-38f0350acbdb"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>2.2 Recommended Dosage for MDD, OCD, PD, and PTSD</title>
                     <text>
                        <paragraph>Therecommendedstartingdosagesandmaximumdosagesofparoxetine tabletsinpatientswithMDD,OCD,PD,andPTSDare presented in Table 1.In patients with an inadequate response, increase dosage in increments of 10 mg per day atintervalsofat least 1 week, depending on tolerability.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Table1:RecommendedDailyDosageofParoxetine TabletsinPatientswithMDD,OCD,PD,andPTSD</content>
                        </paragraph>
                        <table frame="border" rules="all">
                           <tbody>
                              <tr>
                                 <td>
                                    <content styleCode="bold">Indication</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">StartingDose</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">Maximum Dose</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td>MDD</td>
                                 <td>20mg</td>
                                 <td>50mg</td>
                              </tr>
                              <tr>
                                 <td>OCD</td>
                                 <td>20mg</td>
                                 <td>60mg</td>
                              </tr>
                              <tr>
                                 <td>PD</td>
                                 <td>10mg</td>
                                 <td>60mg</td>
                              </tr>
                              <tr>
                                 <td>PTSD</td>
                                 <td>20 mg</td>
                                 <td>50 mg</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph/>
                        <paragraph/>
                     </text>
                     <effectiveTime value="20241219"/>
                  </section>
               </component>
               <component>
                  <section ID="_bb0b2899-d167-0a27-127e-24c660455c02">
                     <id root="ef9fbb34-405d-f119-17de-dde98dd7adcb"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>2.3 Recommended Dosage for SAD and GAD</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">SAD</content>
                        </paragraph>
                        <paragraph>The starting and recommended dosage in patients with SAD is 20 mg daily. In clinical trials theeffectiveness of paroxetine was demonstrated in patients dosed in a range of 20 mg to 60 mg daily.While the safety of paroxetine has been evaluated in patients with SAD at doses up to 60 mg daily,available information does not suggest any additional benefit for doses above 20 mg daily <content styleCode="italics">[seeClinicalStudies(<linkHtml href="#_8d6d1e2b-52b8-a318-0043-ff345d71c6f0">14.4</linkHtml>)].</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">GAD</content>
                        </paragraph>
                        <paragraph>The starting and recommended dosage in patients with GAD is 20 mg daily. In clinical trials theeffectiveness of paroxetine in GAD was demonstrated in patients dosed in a range of 20 mg to 50 mgdaily.Thereisnotsufficientevidencetosuggestagreaterbenefittodoseshigherthan20mgdaily<content styleCode="italics">[seeClinicalStudies(<linkHtml href="#_f95f997f-af31-552a-98d8-3ce397ab16c2">14.5</linkHtml>)].</content>Inpatientswithan<br/>inadequateresponse,increasedosageinincrementsof10mgperdayatintervalsofat least 1week,dependingontolerability.</paragraph>
                     </text>
                     <effectiveTime value="20210531"/>
                  </section>
               </component>
               <component>
                  <section ID="_e67c140b-fa03-cad9-26f1-ff27becbe06b">
                     <id root="7de103a4-ba74-ecce-3128-783b2542bc63"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>2.4 Screen for Bipolar Disorder Prior to Starting Paroxetine Tablets</title>
                     <text>
                        <paragraph>Prior to initiating treatment with paroxetine tablets or another antidepressant, screen patients for a personalorfamilyhistoryofbipolardisorder,mania,orhypomania<content styleCode="italics">[seeWarningsandPrecautions(<linkHtml href="#_5763f641-3be2-01de-77ca-bd14b86b0748">5.6</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20210531"/>
                  </section>
               </component>
               <component>
                  <section ID="_4bfa2214-2145-6513-ebb8-8373f6763bb4">
                     <id root="94eed19c-d9cc-a0d0-eaab-4b45407a2575"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>2.5 Recommended Dosage for Elderly Patients, Patients with Severe Renal Impairment, and Patients with Severe Hepatic Impairment</title>
                     <text>
                        <paragraph>Therecommendedinitialdosageis10mgperdayforelderlypatients,patientswithsevererenalimpairment,andpatientswithsevere hepaticimpairment.Dosageshould notexceed40mg/day.</paragraph>
                     </text>
                     <effectiveTime value="20210531"/>
                  </section>
               </component>
               <component>
                  <section ID="_7909df01-8ad6-251b-2e05-0a6f7a3a24be">
                     <id root="fac0a2ad-a61e-381a-1eab-79d106362504"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>2.6 Switching Patients to or From a Monoamine Oxidase Inhibitor (MAOI)</title>
                     <text>
                        <paragraph>At least 14 days must elapse between discontinuation of a monoamine oxidase inhibitor (MAOIand initiation of paroxetine tablets. In addition, at least 14 days must elapse after stopping paroxetine tablets beforestartinganMAOIantidepressant<content styleCode="italics">[seeContraindications(<linkHtml href="#_321b7fb7-47b4-cee3-aaa7-fdbac8de2624">4</linkHtml>),WarningsandPrecautions(<linkHtml href="#_cc482d0a-c6f1-da5a-37db-cf01b70fbb16">5.2</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20210531"/>
                  </section>
               </component>
               <component>
                  <section ID="_88e1fa31-a607-b448-8211-a537c0ab02b0">
                     <id root="c3790f8e-7b9b-7649-01ba-bd08af3003b2"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>2.7 Discontinuation of Treatment with Paroxetine Tablets</title>
                     <text>
                        <paragraph>Adverse reactions may occur upon discontinuation of paroxetine tablets <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#_374de3a0-febe-dffe-139a-413f4ec088ca">5.7</linkHtml>)]</content>. Gradually reduce the dosage rather than stopping paroxetine tablets abruptly whenever possible.</paragraph>
                     </text>
                     <effectiveTime value="20250103"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="_093bee7f-c111-97bc-8d59-88c145d496f5">
               <id root="8cc7b94e-5fb1-8bbb-a485-735d7bd88068"/>
               <code code="43678-2" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Paroxetine tablets, USP are available as:</paragraph>
                  <list>
                     <item>10 mg white to off-white, oval-shaped, biconvex, film-coated tablet engraved APO &amp; partial bisect score on one side, 097 on the other.</item>
                     <item>20 mg white to off-white, oval-shaped, biconvex, film-coated tablet engraved APO &amp; partial bisect score on one side, 083 on the other.</item>
                     <item> 30mgwhite to off-white, oval-shaped, biconvex, film-coated tablet engraved APO on one side &amp; 084 on the other side.</item>
                     <item>40mgwhite to off-white, oval-shaped, biconvex, film-coated tablet engraved APO on one side &amp; 101 on the other side.</item>
                  </list>
               </text>
               <effectiveTime value="20250103"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list>
                           <item>Extended-release tablets: 10 mg, scored; 20 mg, scored; 30 mg; and 40 mg tablets. (<linkHtml href="#_093bee7f-c111-97bc-8d59-88c145d496f5">3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="_321b7fb7-47b4-cee3-aaa7-fdbac8de2624">
               <id root="59335265-8986-e32a-2f43-8f86135147c2"/>
               <code code="34070-3" displayName="CONTRAINDICATIONS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>Paroxetine tabletsare contraindicatedin patients:</paragraph>
                  <list>
                     <item>Taking, or within 14 days of stopping, MAOIs (including the MAOIs linezolid andintravenous methylene blue) because of an increased risk of serotonin syndrome <content styleCode="italics">[seeWarningsand Precautions (<linkHtml href="#_cc482d0a-c6f1-da5a-37db-cf01b70fbb16">5.2</linkHtml>), Drug Interactions (<linkHtml href="#_98fb8324-731b-1e24-7f26-087b47024334">7</linkHtml>)].</content>
                     </item>
                     <item>Takingthioridazine becauseofrisk of QTprolongation<content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#_d5cd4ce9-823a-e580-7c7e-dc5b09972393">5.3</linkHtml>), Drug Interactions (7)]</content>
                     </item>
                     <item>Takingpimozide because of risk of QT prolongation<content styleCode="italics">[see Warnings and Precautions(<linkHtml href="#_d5cd4ce9-823a-e580-7c7e-dc5b09972393">5.3</linkHtml>),Drug Interactions (<linkHtml href="#_98fb8324-731b-1e24-7f26-087b47024334">7</linkHtml>)]</content>. </item>
                     <item>Withknownhypersensitivity(e.g.,anaphylaxis,angioedema,Stevens-Johnsonsyndrome) to paroxetine or any of the inactive ingredients in paroxetine tablets <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#_5c7b35e4-0c3b-7de7-2c8b-c5e7f77ffcd4">6.1</linkHtml>),(<linkHtml href="#_7cdda414-e252-f29d-b546-6e7e402769b7">6.2</linkHtml>)].</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20250103"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list>
                           <item>Concomitant use of monoamine oxidase inhibitors (MAOIs) or use within 14daysof discontinuing a MAOI.(<linkHtml href="#_321b7fb7-47b4-cee3-aaa7-fdbac8de2624">4</linkHtml>,<linkHtml href="#_d5cd4ce9-823a-e580-7c7e-dc5b09972393">5.3</linkHtml>,<linkHtml href="#_98fb8324-731b-1e24-7f26-087b47024334"> 7</linkHtml>)</item>
                           <item>Concomitantuseofpimozideorthioridazine.(<linkHtml href="#_321b7fb7-47b4-cee3-aaa7-fdbac8de2624">4</linkHtml>,<linkHtml href="#_d5cd4ce9-823a-e580-7c7e-dc5b09972393">5.3</linkHtml>,<linkHtml href="#_98fb8324-731b-1e24-7f26-087b47024334"> 7</linkHtml>)</item>
                           <item>Known hypersensitivity to paroxetine or to any of the inactive ingredients inparoxetine tablets.(<linkHtml href="#_321b7fb7-47b4-cee3-aaa7-fdbac8de2624">4</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="_3516a635-1a59-4b21-5841-244ae146e8a9">
               <id root="614ae2d1-3b57-572c-bdcb-74a88656ca1c"/>
               <code code="43685-7" displayName="WARNINGS AND PRECAUTIONS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20210530"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list>
                           <item>
                              <content styleCode="italics">SerotoninSyndrome:</content>Increasedriskwhenco-administeredwithotherserotonergic agents, but also when taken alone. Ifoccurs,discontinue paroxetine tabletsand serotonergic agents andinitiate supportivemeasures. (<linkHtml href="#_cc482d0a-c6f1-da5a-37db-cf01b70fbb16">5.2</linkHtml>)</item>
                           <item>
                              <content styleCode="italics">EmbryofetalToxicity:</content>May cause fetal harm. Meta-analyses of epidemiological studies have shown increased risk (less than 2-fold) of cardiovascular malformations with exposure during the first trimester. (<linkHtml href="#_25e0dbe0-a5e5-c7fc-94b2-5f1f881cec3d">5.4</linkHtml>, <linkHtml href="#_f8c81c80-1de4-0c58-25c6-63646e66b4a3">8.1</linkHtml>)</item>
                           <item>
                              <content styleCode="italics">Increased Risk of Bleeding:</content> Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs, other antiplatelet drugs, warfarin, and otheranticoagulantdrugs may increase risk. (<linkHtml href="#_653d03c0-3732-f4ff-cd4d-3f78936c5075">5.5</linkHtml>)</item>
                           <item>
                              <content styleCode="italics">ActivationofMania/Hypomania:</content>Screenpatientsforbipolardisorder.(<linkHtml href="#_5763f641-3be2-01de-77ca-bd14b86b0748">5.6</linkHtml>)</item>
                           <item>
                              <content styleCode="italics">Seizures:</content>Usewithcautioninpatientswithseizuredisorders.(<linkHtml href="#_a180853a-73aa-86c1-43d2-35f7d6254bd2">5.8</linkHtml>)</item>
                           <item>
                              <content styleCode="italics">Angle-Closure Glaucoma:</content> Angle-closure glaucoma has occurred in patientswithuntreatedanatomicallynarrowanglestreatedwithantidepressants.(<linkHtml href="#_299dbc05-dee7-d513-22f1-64d9b6f7225a">5.9</linkHtml>)</item>
                           <item>Sexual Dysfunction:Paroxetinemay cause symptoms of sexual dysfunction. (<linkHtml href="#_5237cde6-a03a-a95b-df20-e23a49e6505e">5.13</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="_9dff5b7a-4deb-c87c-5aa7-c4a74463c4e8">
                     <id root="0b23ff42-9c2a-9faa-ddcc-7dcbe79e1782"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title> 5.1 Suicidal Thoughts and Behaviors in Adolescents and Young Adults</title>
                     <text>
                        <paragraph>In pooled analyses of placebo-controlled trials of antidepressant drugs (SSRIs and otherantidepressant classes) that included approximately 77,000 adult patients and 4,500 pediatricpatients, the incidence of suicidal thoughts and behaviors in antidepressant-treated patients age24 years and younger was greater than in placebo-treated patients. There was considerablevariation in risk of suicidal thoughts and behaviors among drugs, but there was an increased riskidentified in young patients for most drugs studied. There were differences in absolute risk ofsuicidal thoughts and behaviors across the different indications, with the highest incidence inpatients with MDD. The drug-placebo differences in the number of cases of suicidal thoughtsandbehaviors per 1,000 patientstreated are provided in Table 2.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 2: </content>
                           <content styleCode="bold">Risk Differences of the Number of Patients with Suicidal Thoughts and Behaviors inthePooledPlacebo-ControlledTrialsofAntidepressantsinPediatricandAdultPatients</content>
                        </paragraph>
                        <table frame="box" rules="all">
                           <tbody align="left">
                              <tr>
                                 <td>
                                    <content styleCode="bold"></content>
                                    <content styleCode="bold">AgeRange</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">Drug-Placebo Difference in Number of Patientswith SuicidalThoughtsand Behaviorsper1,000 Patients Treated</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td></td>
                                 <td>
                                    <content styleCode="bold">IncreasesCompared toPlacebo</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td>&lt;18years old</td>
                                 <td>14 additional cases</td>
                              </tr>
                              <tr>
                                 <td>18 to 24 yearsold</td>
                                 <td>5 additional cases</td>
                              </tr>
                              <tr>
                                 <td></td>
                                 <td>
                                    <content styleCode="bold">DecreasesCompared to Placebo</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td>25 to 64 yearsold</td>
                                 <td>1 fewer case</td>
                              </tr>
                              <tr>
                                 <td> 65yearsold</td>
                                 <td>6fewercases</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Paroxetine is notapproved foruse inpediatric patients.</paragraph>
                        <paragraph>It is unknown whether the risk of suicidal thoughts and behaviors in children, adolescents, andyoung adults extends to longer-term use, i.e., beyond four months. However, there is substantialevidence from placebo-controlled maintenance trials in adults with MDD that antidepressantsdelay the recurrence of depression and that depression itself is a risk factor for suicidal thoughtsandbehaviors.</paragraph>
                        <paragraph>Monitorallantidepressant-treatedpatientsforanyindicationforclinicalworseningandemergenceof suicidal thoughts and behaviors, especially during the initial few months of drug therapy, andat times of dosage changes. Counsel family members or caregivers of patients to monitor forchanges in behavior and to alert the healthcare provider. Consider changing the therapeuticregimen, including possibly discontinuing paroxetine, in patients whose depression is persistentlyworse,or whoare experiencingemergent suicidalthoughts orbehaviors.</paragraph>
                        <paragraph/>
                     </text>
                     <effectiveTime value="20241220"/>
                  </section>
               </component>
               <component>
                  <section ID="_cc482d0a-c6f1-da5a-37db-cf01b70fbb16">
                     <id root="8c76afb5-ea98-3614-b0ac-408ab4cce897"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>  5.2 Serotonin Syndrome</title>
                     <text>
                        <paragraph>
                           <content styleCode="none">S</content>
                           <content styleCode="none">SRIs, including paroxetine, canprecipitate serotonin syndrome, a potentially life-threateningcondition. The risk is increased with concomitant use of other serotonergic drugs (includingtriptans, tricyclic antidepressants, fentanyl, lithium, tramadol, meperidine, methadone, tryptophan, buspirone,amphetaminesand St. Johns Wort) and with drugs that impair metabolism of serotonin, i.e.,MAOIs </content>
                           <content styleCode="italics"> [see Contraindications (<linkHtml href="#_321b7fb7-47b4-cee3-aaa7-fdbac8de2624">4</linkHtml>), Drug Interactions (<linkHtml href="#_98fb8324-731b-1e24-7f26-087b47024334">7.1</linkHtml>)].</content>Serotonin syndrome can also occurwhenthese drugsare usedalone.</paragraph>
                        <paragraph>Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations,delirium, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness,diaphoresis,flushing,hyperthermia),neuromuscularsymptoms(e.g.,tremor,rigidity,myoclonus, hyperreflexia, incoordination), seizures, and/or gastrointestinal symptoms (e.g.,nausea,vomiting, diarrhea).</paragraph>
                        <paragraph>The concomitant use of paroxetine with MAOIs is contraindicated.In addition, do not initiateparoxetine in a patient being treated with MAOIs such as linezolid or intravenous methylene blue.No reports involved the administration of methylene blue by other routes (such as oral tablets orlocal tissue injection) or at lower doses. If it is necessary to initiate treatment with an MAOI suchas linezolid or intravenous methylene blue in a patient taking paroxetine discontinue paroxetine beforeinitiatingtreatment with the MAOI<content styleCode="italics">[seeContraindications (<linkHtml href="#_321b7fb7-47b4-cee3-aaa7-fdbac8de2624">4</linkHtml>), Drug Interactions (<linkHtml href="#_98fb8324-731b-1e24-7f26-087b47024334">7</linkHtml>)].</content>
                        </paragraph>
                        <paragraph>Monitorallpatientstakingparoxetine fortheemergenceofserotoninsyndrome.Discontinuetreatmentwithparoxetine andanyconcomitantserotonergicagentsimmediatelyiftheabovesymptomsoccur, andinitiatesupportivesymptomatic treatment.Ifconcomitantuseofparoxetine withotherserotonergicdrugsis clinicallywarranted, informpatients ofthe increasedriskforserotonin syndromeandmonitorforsymptoms.</paragraph>
                     </text>
                     <effectiveTime value="20250103"/>
                  </section>
               </component>
               <component>
                  <section ID="_d5cd4ce9-823a-e580-7c7e-dc5b09972393">
                     <id root="c046ded7-07e9-0c1d-a316-e3cf1fd81379"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.3 Drug Interactions Leading to QT Prolongation</title>
                     <text>
                        <paragraph>The CYP2D6 inhibitory properties of paroxetine can elevate plasma levels of thioridazine andpimozide. Since thioridazine and pimozide given alone produce prolongation of the QTc intervaland increase the risk of serious ventricular arrhythmias, the use of paroxetine is contraindicated incombination with thioridazine and pimozide <content styleCode="italics">[see Contraindications (<linkHtml href="#_321b7fb7-47b4-cee3-aaa7-fdbac8de2624">4</linkHtml>), Drug Interactions (<linkHtml href="#_3516a635-1a59-4b21-5841-244ae146e8a9">7</linkHtml>),Clinical Pharmacology (<linkHtml href="#_98fb8324-731b-1e24-7f26-087b47024334">12.3</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20210531"/>
                  </section>
               </component>
               <component>
                  <section ID="_25e0dbe0-a5e5-c7fc-94b2-5f1f881cec3d">
                     <id root="bdd58243-7b79-1619-a492-f5ddc0d2c47e"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.4 Embryofetal Toxicity</title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">Based on meta-analyses of epidemiological studies, exposure to paroxetine in the first trimester of pregnancy is associated with a less than 2-fold increase in the rate of cardiovascular malformations among infants. For women who intend to become pregnant or who are in their first trimester of pregnancy, paroxetine, should be initiated only after consideration of the other available treatment options</content>
                           <content styleCode="italics"> [see Use in Specific Populations (<linkHtml href="#_f8c81c80-1de4-0c58-25c6-63646e66b4a3">8.1</linkHtml>)].</content>
                        </paragraph>
                        <paragraph/>
                     </text>
                     <effectiveTime value="20241219"/>
                  </section>
               </component>
               <component>
                  <section ID="_653d03c0-3732-f4ff-cd4d-3f78936c5075">
                     <id root="975c3677-cbee-c43e-11a3-7f8d0814e44e"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.5 Increased Risk of Bleeding</title>
                     <text>
                        <paragraph> Drugs that interfere with serotonin reuptake inhibition, including paroxetine, increase the risk ofbleeding events. Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDS),other antiplatelet drugs, warfarin, and other anticoagulants may add to this risk. Case reports andepidemiological studies (case-control and cohort design) have demonstrated an associationbetween use of drugs that interfere with serotonin reuptake and the occurrence of gastrointestinalbleeding. Based on data from the published observational studies, exposure to SSRIs, particularly in the month before delivery, has been associated with a less than 2-fold increase in the risk of postpartum hemorrhage <br/>
                           <content styleCode="italics"> [see Use in Specific Populations (<linkHtml href="#_f8c81c80-1de4-0c58-25c6-63646e66b4a3">8.1</linkHtml>)] </content>. Bleeding events related to drugs that interfere with serotonin reuptake have rangedfromecchymoses, hematomas,epistaxis, andpetechiae tolife-threatening hemorrhages.</paragraph>
                        <paragraph>Informpatientsabouttheincreasedriskofbleedingassociatedwiththeconcomitantuseofparoxetineand antiplatelet agents or anticoagulants. For patients taking warfarin, carefully monitor theinternationalnormalized ratio.</paragraph>
                     </text>
                     <effectiveTime value="20250103"/>
                  </section>
               </component>
               <component>
                  <section ID="_5763f641-3be2-01de-77ca-bd14b86b0748">
                     <id root="11c29a0f-885b-649d-b5a1-61de7b60a7b4"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.6 Activation of Mania or Hypomania</title>
                     <text>
                        <paragraph>Inpatientswithbipolardisorder,treatingadepressiveepisodewithparoxetine tabletoranotherantidepressantmayprecipitatea mixed/manicepisode. Duringcontrolledclinicaltrialsofparoxetine, hypomaniaormaniaoccurredinapproximately1%ofparoxetine-treated unipolar patientscompared to1.1%ofactive-controland0.3%ofplacebo-treatedunipolarpatients. Priortoinitiatingtreatment with paroxetine, screen patients for any personal or family history of bipolar disorder,mania,or hypomania.</paragraph>
                     </text>
                     <effectiveTime value="20230912"/>
                  </section>
               </component>
               <component>
                  <section ID="_374de3a0-febe-dffe-139a-413f4ec088ca">
                     <id root="385b0129-641c-19cc-91f6-5e14780ac818"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.7 Discontinuation Syndrome</title>
                     <text>
                        <paragraph>Adverse reactions after discontinuation of serotonergic antidepressants, particularly after abruptdiscontinuation, include: nausea, sweating, dysphoric mood, irritability, agitation, dizziness,sensory disturbances (e.g., paresthesia, such as electric shock sensations), tremor, anxiety,confusion, headache, lethargy, emotional lability, insomnia, hypomania, tinnitus, and seizures. Agradual reduction in dosage rather than abrupt cessation is recommended whenever possible <content styleCode="italics">[see DosageandAdministration(<linkHtml href="#_88e1fa31-a607-b448-8211-a537c0ab02b0">2.7</linkHtml>)].</content>
                        </paragraph>
                        <paragraph>During clinical trials of GAD and PTSD, gradual decreases in the daily dose by 10 mg/day atweekly intervals followed by 1 week at 20 mg/day was used before treatment was discontinued.Thefollowingadversereactionswerereported atanincidence of2%or greaterforparoxetine and were at least twice that reported for placebo: Abnormal dreams, paresthesia, and dizzinessadverse reactions have been reported upon discontinuation of treatment with paroxetine in pediatricpatients. The safety and effectiveness of paroxetine in pediatric patients have not been established<content styleCode="italics">[seeBoxedWarning,WarningsandPrecautions(<linkHtml href="#_9dff5b7a-4deb-c87c-5aa7-c4a74463c4e8">5.1</linkHtml>), Use in Specific Populations (<linkHtml href="#_f399a731-bb7e-72b7-ef00-b849dffcc08e">8.4</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20230912"/>
                  </section>
               </component>
               <component>
                  <section ID="_a180853a-73aa-86c1-43d2-35f7d6254bd2">
                     <id root="4ea08b7a-f3ea-153c-c50a-2c219f243978"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.8 Seizures</title>
                     <text>
                        <paragraph>Paroxetine tabletshavenotbeensystematicallyevaluatedinpatientswithseizuredisorders. Patients with history of seizures were excluded from clinical studies. During clinicalstudies, seizures occurred in 0.1% of patients treated with paroxetine. Paroxetine should be prescribedwith caution in patients with a seizure disorder. Discontinue paroxetine in any patient who developsseizures.</paragraph>
                     </text>
                     <effectiveTime value="20210531"/>
                  </section>
               </component>
               <component>
                  <section ID="_299dbc05-dee7-d513-22f1-64d9b6f7225a">
                     <id root="850b9267-9fd8-7102-d3c0-09e6c1cf2784"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.9 Angle-Closure Glaucoma</title>
                     <text>
                        <paragraph>The pupillary dilation that occurs following use of many antidepressant drugs including paroxetinemay trigger an angle closure attack in a patient with anatomically narrow angles who does nothave a patent iridectomy. Cases of angle-closure glaucoma associated with use of paroxetine havebeenreported.Avoiduseofantidepressants,includingparoxetine inpatientswithuntreatedanatomicallynarrow angles.</paragraph>
                     </text>
                     <effectiveTime value="20250103"/>
                  </section>
               </component>
               <component>
                  <section ID="_3df0fa0a-0e52-aebd-c77a-7d136531d8ae">
                     <id root="6247715c-24f9-5a63-6cb1-954af876d4f8"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.10 Hyponatremia</title>
                     <text>
                        <paragraph>Hyponatremia may occur as a result of treatment with SSRIs, including paroxetine. Cases withserumsodiumlowerthan 110mmol/L have beenreported.Signsandsymptomsofhyponatremiainclude headache, difficulty concentrating, memory impairment, confusion, weakness, andunsteadiness, which may lead to falls. Signs and symptoms associated with more severe and/oracute cases have included hallucination, syncope, seizure, coma, respiratory arrest, and death.Inmany cases, this hyponatremia appears to be the result of the syndrome of inappropriateantidiuretichormone secretion (SIADH).</paragraph>
                        <paragraph>Inpatientswithsymptomatichyponatremia,discontinueparoxetine tablet andinstituteappropriatemedicalintervention. Elderly patients, patients taking diuretics, and those who are volume-depleted maybeatgreaterriskofdeveloping hyponatremiawithSSRIs <content styleCode="italics">[seeUseinSpecificPopulations(<linkHtml href="#_b3cc2bac-7000-420c-92ef-88bdefadade5">8.5</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20211030"/>
                  </section>
               </component>
               <component>
                  <section ID="_128b39fe-9a39-3ec7-99a3-672ce8d35f3d">
                     <id root="627bd77d-25e5-5861-496e-09f1cce66413"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.11 Reduction of Efficacy of Tamoxifen</title>
                     <text>
                        <paragraph>Some studies have shown that the efficacy of tamoxifen, as measured by the risk of breast cancerrelapse/mortality, may be reduced with concomitant use of paroxetine as a result of paroxetinesirreversible inhibition of CYP2D6 and lower blood levels of tamoxifen <content styleCode="italics">[see Drug Interactions(<linkHtml href="#_98fb8324-731b-1e24-7f26-087b47024334">7</linkHtml>)].</content> One study suggests that the risk may increase with longer duration of coadministration.However, other studies have failed to demonstrate such a risk. When tamoxifen is used for thetreatmentorpreventionofbreastcancer,prescribersshouldconsider usingan alternativeantidepressantwith little or no CYP2D6 inhibition.</paragraph>
                     </text>
                     <effectiveTime value="20211030"/>
                  </section>
               </component>
               <component>
                  <section ID="_fb0f2864-4c62-d978-2c07-83db7c2cc0c8">
                     <id root="5c87b84f-7c05-756f-641b-d2f889f9ccd4"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.12 Bone Fracture</title>
                     <text>
                        <paragraph>Epidemiological studies on bone fracture risk during exposure to some antidepressants, includingSSRIs,havereportedan association betweenantidepressanttreatmentandfractures.Therearemultiplepossiblecausesforthisobservation, anditisunknowntowhat<br/>extentfractureriskisdirectlyattributabletoSSRItreatment.</paragraph>
                     </text>
                     <effectiveTime value="20250103"/>
                  </section>
               </component>
               <component>
                  <section ID="_5237cde6-a03a-a95b-df20-e23a49e6505e">
                     <id root="c487b498-9f7f-4092-b975-080bb145768a"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>
                        <content styleCode="none"> 5.13 Sexual Dysfunction </content>
                     </title>
                     <text>
                        <paragraph>Use of SSRIs, including paroxetine, may cause symptoms of sexual dysfunction <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#_5c7b35e4-0c3b-7de7-2c8b-c5e7f77ffcd4">6.1</linkHtml>)]</content>. In male patients, SSRI use may result in ejaculatory delay or failure, decreased libido, and erectile dysfunction. In female patients, SSRI use may result in decreased libido and delayed or absent orgasm. </paragraph>
                        <paragraph>It is important for prescribers to inquire about sexual function prior to initiation of paroxetine and to inquire specifically about changes in sexual function during treatment, because sexual function may not be spontaneously reported. When evaluating changes in sexual function, obtaining a detailed history (including timing of symptom onset) is important because sexual symptoms may have other causes, including the underlying psychiatric disorder. Discuss potential management strategies to support patients in making informed decisions about treatment.</paragraph>
                     </text>
                     <effectiveTime value="20241220"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="_3ddce09e-36ad-1d03-4a4a-b681c6094b08">
               <id root="c1aa5aac-5001-58e3-d6bb-3e717d4cb482"/>
               <code code="34084-4" displayName="ADVERSE REACTIONS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>Thefollowingadversereactionsareincludedinmoredetailinothersectionsoftheprescribinginformation:</paragraph>
                  <list>
                     <item>Hypersensitivityreactionstoparoxetine<content styleCode="italics">[seeContraindications(<linkHtml href="#_321b7fb7-47b4-cee3-aaa7-fdbac8de2624">4</linkHtml>)]</content>
                     </item>
                     <item>SuicidalThoughtsandBehaviors<content styleCode="italics">[seeWarningsandPrecautions(<linkHtml href="#_321b7fb7-47b4-cee3-aaa7-fdbac8de2624">5.1</linkHtml>)]</content>
                     </item>
                     <item>SerotoninSyndrome<content styleCode="italics">[seeWarningsandPrecautions(<linkHtml href="#_9dff5b7a-4deb-c87c-5aa7-c4a74463c4e8">5.2</linkHtml>)]</content>
                     </item>
                     <item>EmbryofetalToxicity<content styleCode="italics">[seeWarningsandPrecautions(<linkHtml href="#_cc482d0a-c6f1-da5a-37db-cf01b70fbb16">5.4</linkHtml>)]</content>
                     </item>
                     <item>IncreasedRiskofBleeding<content styleCode="italics">[seeWarningsandPrecautions(<linkHtml href="#_25e0dbe0-a5e5-c7fc-94b2-5f1f881cec3d">5.5</linkHtml>)]</content>
                     </item>
                     <item>ActivationofMania/Hypomania<content styleCode="italics">[seeWarningsandPrecautions(<linkHtml href="#_653d03c0-3732-f4ff-cd4d-3f78936c5075">5.6</linkHtml>)]</content>
                     </item>
                     <item>DiscontinuationSyndrome<content styleCode="italics">[seeWarningsandPrecautions(<linkHtml href="#_5763f641-3be2-01de-77ca-bd14b86b0748">5.7</linkHtml>)]</content>
                     </item>
                     <item>Seizures<content styleCode="italics">[seeWarningsandPrecautions(<linkHtml href="#_374de3a0-febe-dffe-139a-413f4ec088ca">5.8</linkHtml>)]</content>
                     </item>
                     <item>Angle-closureGlaucoma<content styleCode="italics">[seeWarningsandPrecautions(<linkHtml href="#_a180853a-73aa-86c1-43d2-35f7d6254bd2">5.9</linkHtml>)]</content>
                     </item>
                     <item>Hyponatremia<content styleCode="italics">[seeWarningsandPrecautions(<linkHtml href="#_299dbc05-dee7-d513-22f1-64d9b6f7225a">5.10</linkHtml>)]</content>
                     </item>
                     <item>BoneFracture<content styleCode="italics">[seeWarningsandPrecautions(<linkHtml href="#_fb0f2864-4c62-d978-2c07-83db7c2cc0c8">5.12</linkHtml>)]</content>
                     </item>
                     <item>Sexual Dysfunction <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#_5237cde6-a03a-a95b-df20-e23a49e6505e">5.13</linkHtml>)</content>
                        <content styleCode="italics">]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20241219"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Most common adverse reactions (5% and at least twice placebo) areabnormal ejaculation, asthenia, constipation, decreased appetite, diarrhea,dizziness, dry mouth, female genital disorder, impotence, infection, insomnia,libido decreased, male genital disorder, nausea, nervousness, somnolence,sweating,tremor,yawn. (<linkHtml href="#_3ddce09e-36ad-1d03-4a4a-b681c6094b08">6</linkHtml>)</paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Apotex Corp. at 1-800-706-5575 or FDA at 1-800-FDA-1088 or </content>
                           <content styleCode="bold italics underline"/>
                           <content styleCode="italics underline">
                              <linkHtml href="#_8159213C-7EE2-2385-46F4-473276BA8961"> www.fda.gov/medwatch</linkHtml> . </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="_5c7b35e4-0c3b-7de7-2c8b-c5e7f77ffcd4">
                     <id root="cd6e1013-9d70-f3d1-f449-f09e6e6693cb"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>6.1 Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction ratesobserved in the clinical trials of a drug cannot be directly compared to rates in the clinical trialsofanother drugand may notreflect the ratesobservedin practice.</paragraph>
                        <paragraph>Thesafetydataforparoxetine arefrom:</paragraph>
                        <list>
                           <item>6-weekclinicaltrials inMDDpatients whoreceived paroxetine 20mgto 50mgonce daily</item>
                           <item>12-weekclinicaltrialsinOCDpatientswhoreceivedparoxetine20 mgto60mgonce daily</item>
                           <item>10-to12-weekclinicaltrialsinPDpatientswhoreceivedparoxetine10mgto60mg once daily</item>
                           <item>12-weekclinicaltrialsinSADpatientswhoreceived paroxetine20 mgto50mgonce daily</item>
                           <item>8-weekclinicaltrials inGADpatientswhoreceived paroxetine10 mgto50 mgonce daily</item>
                           <item>12-weekclinicaltrialsinPTSDpatientswhoreceivedparoxetine20mgto50mgoncedaily</item>
                        </list>
                        <paragraph>
                           <content styleCode="underline"/>
                           <content styleCode="underline">AdverseReactionsLeadingtoDiscontinuation</content>
                        </paragraph>
                        <paragraph>Twenty percent (1,199/6,145) of patients treated with paroxetine in clinical trials in MDD and16.1%(84/522),11.8%(64/542),9.4%(44/469),10.7%(79/735),and11.7%(79/676)of patients treated with paroxetine in clinical trials in SAD, OCD, PD, GAD, and PTSD, respectively,discontinued treatment due to an adverse reaction. The most common adverse reactions (1%)associated with discontinuation (i.e., those adverse reactions associated with dropout at a rateapproximatelytwice orgreater for paroxetinecompared to placebo)are presented inTable 3:</paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 3: Adverse Reactions Reported as Leading to Discontinuation (1% of Paroxetine-TreatedPatientsand Greaterthan Placebo)in MDD,OCD, PD,SAD, GAD,and PTSDTrials</content>
                        </paragraph>
                        <table frame="box" rules="all">
                           <tbody align="center">
                              <tr>
                                 <td rowspan="2"></td>
                                 <td colspan="2">
                                    <content styleCode="bold">MDD</content>
                                 </td>
                                 <td colspan="2">
                                    <content styleCode="bold">OCD</content>
                                 </td>
                                 <td colspan="2">
                                    <content styleCode="bold">PD</content>
                                 </td>
                                 <td colspan="2">
                                    <content styleCode="bold">SAD</content>
                                 </td>
                                 <td colspan="2">
                                    <content styleCode="bold">GAD</content>
                                 </td>
                                 <td colspan="2">
                                    <content styleCode="bold">PTSD</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td>
                                    <content styleCode="bold">Paroxetine</content>
                                    <br/>
                                    <content styleCode="bold">%</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">Placebo</content>
                                    <br/>
                                    <content styleCode="bold">%</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">Paroxetine</content>
                                    <br/>
                                    <content styleCode="bold">%</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">Placebo<br/>
                                    </content>
                                    <content styleCode="bold">%</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">Paroxetine</content>
                                    <br/>
                                    <content styleCode="bold">%</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">Placebo</content>
                                    <br/>
                                    <content styleCode="bold">%</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">Paroxetine</content>
                                    <content styleCode="bold">
                                       <br/>%</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">Placebo</content>
                                    <content styleCode="bold">
                                       <br/>%</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">Paroxetine</content>
                                    <content styleCode="bold">
                                       <br/>%</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">Placebo</content>
                                    <content styleCode="bold">
                                       <br/>%</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">Paroxetine </content>
                                    <content styleCode="bold">
                                       <br/>%</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">Placebo</content>
                                    <content styleCode="bold">
                                       <br/>%</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td>
                                    <content styleCode="bold">CNS</content>
                                 </td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                              </tr>
                              <tr>
                                 <td>Somnolence</td>
                                 <td>2.3</td>
                                 <td>0.7</td>
                                 <td></td>
                                 <td></td>
                                 <td>1.9</td>
                                 <td>0.3</td>
                                 <td>3.4</td>
                                 <td>0.3</td>
                                 <td>2</td>
                                 <td>0.2</td>
                                 <td>2.8</td>
                                 <td>0.6</td>
                              </tr>
                              <tr>
                                 <td>Insomnia</td>
                                 <td></td>
                                 <td></td>
                                 <td>1.7</td>
                                 <td>0</td>
                                 <td>1.3</td>
                                 <td>0.3</td>
                                 <td>3.1</td>
                                 <td>0</td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                              </tr>
                              <tr>
                                 <td>Agitation</td>
                                 <td>1.1</td>
                                 <td>0.5</td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                              </tr>
                              <tr>
                                 <td>Tremor</td>
                                 <td>1.1</td>
                                 <td>0.3</td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td>1.7</td>
                                 <td>0</td>
                                 <td></td>
                                 <td></td>
                                 <td>1</td>
                                 <td>0.2</td>
                              </tr>
                              <tr>
                                 <td>Anxiety</td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td>1.1</td>
                                 <td>0</td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                              </tr>
                              <tr>
                                 <td>Dizziness</td>
                                 <td></td>
                                 <td></td>
                                 <td>1.5</td>
                                 <td>0</td>
                                 <td></td>
                                 <td></td>
                                 <td>1.9</td>
                                 <td>0</td>
                                 <td>1</td>
                                 <td>0.2</td>
                                 <td></td>
                                 <td></td>
                              </tr>
                              <tr>
                                 <td rowspan="2">
                                    <content styleCode="bold">Gastroin-</content>
                                    <content styleCode="bold">testinal</content>
                                 </td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                              </tr>
                              <tr>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                              </tr>
                              <tr>
                                 <td>Constipation</td>
                                 <td></td>
                                 <td></td>
                                 <td>1.1</td>
                                 <td>0</td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                              </tr>
                              <tr>
                                 <td>Nausea</td>
                                 <td>3.2</td>
                                 <td>1.1</td>
                                 <td>1.9</td>
                                 <td>0</td>
                                 <td>3.2</td>
                                 <td>1.2</td>
                                 <td>4</td>
                                 <td>0.3</td>
                                 <td>2</td>
                                 <td>0.2</td>
                                 <td>2.2</td>
                                 <td>0.6</td>
                              </tr>
                              <tr>
                                 <td>Diarrhea</td>
                                 <td>1</td>
                                 <td>0.3</td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                              </tr>
                              <tr>
                                 <td>Drymouth</td>
                                 <td>1</td>
                                 <td>0.3</td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                              </tr>
                              <tr>
                                 <td>Vomiting</td>
                                 <td>1</td>
                                 <td>0.3</td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td>1</td>
                                 <td> 0</td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                              </tr>
                              <tr>
                                 <td>Flatulence</td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td>1</td>
                                 <td>0.3</td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                              </tr>
                              <tr>
                                 <td>
                                    <content styleCode="bold">Other</content>
                                 </td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td rowspan="7"></td>
                                 <td rowspan="7"></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                              </tr>
                              <tr>
                                 <td>Asthenia</td>
                                 <td>1.6</td>
                                 <td>0.4</td>
                                 <td>1.9</td>
                                 <td>0.4</td>
                                 <td>2.5</td>
                                 <td>0.6</td>
                                 <td>1.8</td>
                                 <td>0.2</td>
                                 <td>1.6</td>
                                 <td>0.2</td>
                              </tr>
                              <tr>
                                 <td>Abnormal</td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                              </tr>
                              <tr>
                                 <td>Ejaculation<sup>a</sup>
                                 </td>
                                 <td>1.6</td>
                                 <td>0</td>
                                 <td>2.1</td>
                                 <td>0</td>
                                 <td>4.9</td>
                                 <td>0.6</td>
                                 <td>2.5</td>
                                 <td>0.5</td>
                                 <td></td>
                                 <td></td>
                              </tr>
                              <tr>
                                 <td>Sweating</td>
                                 <td>1</td>
                                 <td>0.3</td>
                                 <td></td>
                                 <td></td>
                                 <td>1.1</td>
                                 <td>0</td>
                                 <td>1.1</td>
                                 <td>0.2</td>
                                 <td></td>
                                 <td></td>
                              </tr>
                              <tr>
                                 <td>Impotence<sup>a</sup>
                                 </td>
                                 <td></td>
                                 <td></td>
                                 <td>1.5</td>
                                 <td>0</td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                              </tr>
                              <tr>
                                 <td>Libido Decreased</td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td>1</td>
                                 <td>0</td>
                                 <td></td>
                                 <td></td>
                                 <td> ---</td>
                                 <td> ---</td>
                              </tr>
                           </tbody>
                        </table>
                        <br/>
                        <br/>
                        <paragraph>Where numbers are not provided the incidence of the adverse reactions in patients treated withparoxetine was not&gt;1% orwas notgreater thanor equalto 2times theincidence ofplacebo.<br/>
                           <sup>a.</sup>Incidence corrected for gender.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Most Common AdverseReactions</content>
                        </paragraph>
                        <paragraph>The most commonly observed adverse reactions associated with the use of paroxetine (incidence of5%or greater and at least twice that for placebo) were:</paragraph>
                        <paragraph>
                           <content styleCode="italics">MDD:</content> Asthenia, sweating, nausea, decreased appetite, somnolence, dizziness, insomnia, tremor,nervousness,ejaculatorydisturbance,andothermalegenitaldisorders.</paragraph>
                        <paragraph>
                           <content styleCode="italics">OCD:</content>Nausea,drymouth,decreasedappetite,constipation,dizziness,somnolence,tremor,sweating,impotence, andabnormal ejaculation.</paragraph>
                        <paragraph>
                           <content styleCode="italics">PD: </content>Asthenia, sweating, decreased appetite, libido decreased, tremor, abnormal ejaculation,femalegenital disorders, and impotence.</paragraph>
                        <paragraph>
                           <content styleCode="italics">SAD: </content>Sweating, nausea, dry mouth, constipation, decreased appetite, somnolence, tremor, libidodecreased,yawn, abnormalejaculation, femalegenital disorders,and impotence.</paragraph>
                        <paragraph>
                           <content styleCode="italics">GAD: </content>Asthenia, infection, constipation, decreased appetite, dry mouth, nausea, libido decreased,somnolence,tremor, sweating, and abnormal ejaculation.</paragraph>
                        <paragraph>
                           <content styleCode="italics">PTSD: </content>Asthenia, sweating, nausea, dry mouth, diarrhea, decreased appetite, somnolence, libidodecreased,abnormal ejaculation, female genital disorders,andimpotence.</paragraph>
                        <paragraph>
                           <content styleCode="underline">AdverseReactionsin PatientswithMDD</content>
                        </paragraph>
                        <paragraph>Table4presentstheadversereactionsthatoccurredatanincidenceof1%ormoreandgreaterthanplacebo inclinical trialsofparoxetine-treatedpatients withMDD.</paragraph>
                        <paragraph>
                           <content styleCode="bold"></content>
                           <content styleCode="bold">Table 4: Adverse Reactions (1% of Paroxetine-Treated Patients and </content>
                           <content styleCode="bold">Greater than Placebo) in 6-WeekClinicalTrialsforMDD</content>
                        </paragraph>
                        <table frame="box" rules="all">
                           <tbody>
                              <tr>
                                 <td>
                                    <content styleCode="bold"></content>
                                    <content styleCode="bold">Body System/AdverseReaction</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">Paroxetine<br/>(n=421)</content>
                                    <br/>
                                    <content styleCode="bold">%</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">Placebo<br/>(n=421)<br/>
                                    </content>
                                    <content styleCode="bold">%</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td>
                                    <content styleCode="bold">Body as a Whole</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold"></content></td>
                                 <td></td>
                              </tr>
                              <tr>
                                 <td>Headache</td>
                                 <td>18</td>
                                 <td>17</td>
                              </tr>
                              <tr>
                                 <td>Asthenia<content styleCode="bold"/>
                                 </td>
                                 <td>15</td>
                                 <td>6</td>
                              </tr>
                              <tr>
                                 <td>
                                    <content styleCode="bold">Cardiovascular</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold"></content></td>
                                 <td>
                                    <content styleCode="bold"></content></td>
                              </tr>
                              <tr>
                                 <td>Palpitation</td>
                                 <td>3</td>
                                 <td>1</td>
                              </tr>
                              <tr>
                                 <td>Vasodilation<content styleCode="bold"/>
                                 </td>
                                 <td>3</td>
                                 <td>1</td>
                              </tr>
                              <tr>
                                 <td>
                                    <content styleCode="bold">Dermatologic</content>
                                 </td>
                                 <td></td>
                                 <td></td>
                              </tr>
                              <tr>
                                 <td>Sweating</td>
                                 <td>11</td>
                                 <td>2</td>
                              </tr>
                              <tr>
                                 <td>Rash<content styleCode="bold"/>
                                 </td>
                                 <td>2</td>
                                 <td>1</td>
                              </tr>
                              <tr>
                                 <td>
                                    <content styleCode="bold">Gastrointestinal</content>
                                 </td>
                                 <td></td>
                                 <td></td>
                              </tr>
                              <tr>
                                 <td>Nausea</td>
                                 <td>26</td>
                                 <td>9</td>
                              </tr>
                              <tr>
                                 <td>DryMouth</td>
                                 <td>18</td>
                                 <td>12</td>
                              </tr>
                              <tr>
                                 <td>Constipation</td>
                                 <td>14</td>
                                 <td>9</td>
                              </tr>
                              <tr>
                                 <td>Diarrhea</td>
                                 <td>12</td>
                                 <td>8</td>
                              </tr>
                              <tr>
                                 <td>Decreased Appetite</td>
                                 <td>6</td>
                                 <td>2</td>
                              </tr>
                              <tr>
                                 <td>Flatulence<content styleCode="bold"/>
                                 </td>
                                 <td>4</td>
                                 <td>2</td>
                              </tr>
                              <tr>
                                 <td>OropharynxDisorder<sup>a</sup>
                                 </td>
                                 <td>2</td>
                                 <td>0</td>
                              </tr>
                              <tr>
                                 <td>Dyspepsia<content styleCode="bold"/>
                                 </td>
                                 <td>2</td>
                                 <td>1</td>
                              </tr>
                              <tr>
                                 <td>
                                    <content styleCode="bold">Musculoskeletal </content>
                                 </td>
                                 <td></td>
                                 <td></td>
                              </tr>
                              <tr>
                                 <td>Myopathy</td>
                                 <td>2</td>
                                 <td>1</td>
                              </tr>
                              <tr>
                                 <td>Myalgia</td>
                                 <td>2</td>
                                 <td>0</td>
                              </tr>
                              <tr>
                                 <td>Myasthenia<content styleCode="bold"/>
                                 </td>
                                 <td>1</td>
                                 <td>1</td>
                              </tr>
                              <tr>
                                 <td>
                                    <content styleCode="bold">NervousSystem</content>
                                 </td>
                                 <td></td>
                                 <td></td>
                              </tr>
                              <tr>
                                 <td>Somnolence<content styleCode="bold"/>
                                 </td>
                                 <td>23</td>
                                 <td>9</td>
                              </tr>
                              <tr>
                                 <td>Dizziness</td>
                                 <td>13</td>
                                 <td>6</td>
                              </tr>
                              <tr>
                                 <td>Insomnia<content styleCode="bold"/>
                                 </td>
                                 <td>13</td>
                                 <td>6</td>
                              </tr>
                              <tr>
                                 <td>Tremor</td>
                                 <td>8</td>
                                 <td>2</td>
                              </tr>
                              <tr>
                                 <td>Nervousness</td>
                                 <td>5</td>
                                 <td>3</td>
                              </tr>
                              <tr>
                                 <td>Anxiety</td>
                                 <td>5</td>
                                 <td>3</td>
                              </tr>
                              <tr>
                                 <td>Paresthesia</td>
                                 <td>4</td>
                                 <td>2</td>
                              </tr>
                              <tr>
                                 <td>Libido Decreased</td>
                                 <td>3</td>
                                 <td>0</td>
                              </tr>
                              <tr>
                                 <td>DruggedFeeling</td>
                                 <td>2</td>
                                 <td>1</td>
                              </tr>
                              <tr>
                                 <td>Confusion<content styleCode="bold"/>
                                 </td>
                                 <td>1</td>
                                 <td>0</td>
                              </tr>
                              <tr>
                                 <td>
                                    <content styleCode="bold">Respiration</content>
                                 </td>
                                 <td></td>
                                 <td></td>
                              </tr>
                              <tr>
                                 <td>Yawn<content styleCode="bold"/>
                                 </td>
                                 <td>4</td>
                                 <td>0</td>
                              </tr>
                              <tr>
                                 <td>
                                    <content styleCode="bold">Special Senses </content>
                                 </td>
                                 <td></td>
                                 <td></td>
                              </tr>
                              <tr>
                                 <td>Blurred Vision</td>
                                 <td>4</td>
                                 <td>1</td>
                              </tr>
                              <tr>
                                 <td>Taste Prevention</td>
                                 <td>2</td>
                                 <td>0</td>
                              </tr>
                              <tr>
                                 <td>
                                    <content styleCode="bold">Urogenital System</content>
                                 </td>
                                 <td></td>
                                 <td></td>
                              </tr>
                              <tr>
                                 <td>Ejaculatory Disturbance <sup>b,c</sup>
                                 </td>
                                 <td>13</td>
                                 <td>0</td>
                              </tr>
                              <tr>
                                 <td>Other Male Genital Disorders <sup>b,d</sup>
                                 </td>
                                 <td>10</td>
                                 <td>0</td>
                              </tr>
                              <tr>
                                 <td>Urinary Frequency</td>
                                 <td>3</td>
                                 <td>1</td>
                              </tr>
                              <tr>
                                 <td>Urination Disorder <sup>e</sup>
                                 </td>
                                 <td>3</td>
                                 <td>0</td>
                              </tr>
                              <tr>
                                 <td>Female Genital Disorders <sup>b,f</sup>
                                 </td>
                                 <td>2</td>
                                 <td>0</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph> a.Includesmostlylumpinthroatandtightnessinthroat.<sup/>
                        </paragraph>
                        <paragraph> b.Percentagecorrectedforgender.<sup/>
                        </paragraph>
                        <paragraph> c.Mostlyejaculatorydelay.<sup/>
                        </paragraph>
                        <paragraph>d.Includes anorgasmia, erectile difficulties, delayed ejaculation/orgasm, and sexual dysfunction, andimpotence.<sup/>
                        </paragraph>
                        <paragraph> e.Includesmostlydifficultywithmicturitionandurinaryhesitancy.</paragraph>
                        <paragraph> f.Includesmostlyanorgasmiaanddifficultyreachingclimax/orgasm.</paragraph>
                        <paragraph>
                           <content styleCode="underline">AdverseReactionsinPatientswithOCD,PD,andSAD</content>
                        </paragraph>
                        <paragraph>Table 5 presents adverse reactions that occurred at a frequency of 2% or more in clinical trials inpatientswithOCD, PD, and SAD.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 5. Adverse Reactions (2% of Paroxetine-Treated Patients and Greater than Placebo) in10to 12-Week Clinical TrialsforOCD,PD,andSAD</content>
                        </paragraph>
                        <table frame="box" rules="all">
                           <tbody>
                              <tr>
                                 <td rowspan="2">
                                    <content styleCode="bold"></content>
                                    <content styleCode="bold">BodySystem/Preferred Term</content>
                                 </td>
                                 <td colspan="2">
                                    <content styleCode="bold">Obsessive CompulsiveDisorder</content>
                                 </td>
                                 <td colspan="2">
                                    <content styleCode="bold">PanicDisorder</content>
                                 </td>
                                 <td colspan="2">
                                    <content styleCode="bold">Social AnxietyDisorder</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td>
                                    <content styleCode="bold">Paroxetine<br/> (n=542)<br/> %</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">Placebo<br/>(n=265)<br/> %</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">Paroxetine<br/>(n=469) <br/>%</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">Placebo<br/>(n=324) <br/>%</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">Paroxetine<br/> (n=425) <br/>%</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">Placebo<br/>(n=339) <br/>%</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td>
                                    <content styleCode="bold">Bodyasa Whole</content>
                                 </td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                              </tr>
                              <tr>
                                 <td>Asthenia</td>
                                 <td>22</td>
                                 <td>14</td>
                                 <td>14</td>
                                 <td>5</td>
                                 <td>22</td>
                                 <td>14</td>
                              </tr>
                              <tr>
                                 <td>AbdominalPain</td>
                                 <td>-</td>
                                 <td>-</td>
                                 <td>4</td>
                                 <td>3</td>
                                 <td></td>
                                 <td></td>
                              </tr>
                              <tr>
                                 <td>ChestPain</td>
                                 <td>3</td>
                                 <td>2</td>
                                 <td>-</td>
                                 <td>-</td>
                                 <td>-</td>
                                 <td>-</td>
                              </tr>
                              <tr>
                                 <td>BackPain</td>
                                 <td>-</td>
                                 <td>-</td>
                                 <td>3</td>
                                 <td>2</td>
                                 <td>-</td>
                                 <td>-</td>
                              </tr>
                              <tr>
                                 <td>Chills</td>
                                 <td>2</td>
                                 <td>1</td>
                                 <td>2</td>
                                 <td>1</td>
                                 <td></td>
                                 <td></td>
                              </tr>
                              <tr>
                                 <td>Trauma</td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td>3</td>
                                 <td>1</td>
                              </tr>
                              <tr>
                                 <td>
                                    <content styleCode="bold">Cardiovascular</content>
                                 </td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                              </tr>
                              <tr>
                                 <td>Vasodilation</td>
                                 <td>4</td>
                                 <td>1</td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                              </tr>
                              <tr>
                                 <td>Palpitation</td>
                                 <td>2</td>
                                 <td>0</td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                              </tr>
                              <tr>
                                 <td>
                                    <content styleCode="bold">Dermatologic</content>
                                 </td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                              </tr>
                              <tr>
                                 <td>Sweating</td>
                                 <td>9</td>
                                 <td>3</td>
                                 <td>14</td>
                                 <td>6</td>
                                 <td>9</td>
                                 <td>2</td>
                              </tr>
                              <tr>
                                 <td>Rash</td>
                                 <td>3</td>
                                 <td>2</td>
                                 <td>-</td>
                                 <td>-</td>
                                 <td>-</td>
                                 <td>-</td>
                              </tr>
                              <tr>
                                 <td>
                                    <content styleCode="bold">Gastrointestinal</content>
                                 </td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                              </tr>
                              <tr>
                                 <td>Nausea</td>
                                 <td>23</td>
                                 <td>10</td>
                                 <td>23</td>
                                 <td>17</td>
                                 <td>25</td>
                                 <td>7</td>
                              </tr>
                              <tr>
                                 <td>DryMouth</td>
                                 <td>18</td>
                                 <td>9</td>
                                 <td>18</td>
                                 <td>11</td>
                                 <td>9</td>
                                 <td>3</td>
                              </tr>
                              <tr>
                                 <td>Constipation</td>
                                 <td>16</td>
                                 <td>6</td>
                                 <td>8</td>
                                 <td>5</td>
                                 <td>5</td>
                                 <td>2</td>
                              </tr>
                              <tr>
                                 <td>Diarrhea</td>
                                 <td>10</td>
                                 <td>10</td>
                                 <td>12</td>
                                 <td>7</td>
                                 <td>9</td>
                                 <td>6</td>
                              </tr>
                              <tr>
                                 <td>Decreased</td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                              </tr>
                              <tr>
                                 <td>Appetite</td>
                                 <td>9</td>
                                 <td>3</td>
                                 <td>7</td>
                                 <td>3</td>
                                 <td>8</td>
                                 <td>2</td>
                              </tr>
                              <tr>
                                 <td>Dyspepsia</td>
                                 <td>-</td>
                                 <td>-</td>
                                 <td>-</td>
                                 <td>-</td>
                                 <td>4</td>
                                 <td>2</td>
                              </tr>
                              <tr>
                                 <td>Flatulence</td>
                                 <td>-</td>
                                 <td>-</td>
                                 <td>-</td>
                                 <td>-</td>
                                 <td>4</td>
                                 <td>2</td>
                              </tr>
                              <tr>
                                 <td>IncreasedAppetite</td>
                                 <td>4</td>
                                 <td>3</td>
                                 <td>2</td>
                                 <td>1</td>
                                 <td>-</td>
                                 <td>-</td>
                              </tr>
                              <tr>
                                 <td>Vomiting</td>
                                 <td>-</td>
                                 <td>-</td>
                                 <td>-</td>
                                 <td>-</td>
                                 <td>2</td>
                                 <td>1</td>
                              </tr>
                              <tr>
                                 <td>
                                    <content styleCode="bold">Musculoskeletal</content>
                                 </td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                              </tr>
                              <tr>
                                 <td>Myalgia</td>
                                 <td>
                                    <content styleCode="bold">-</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">-</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">-</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">-</content>
                                 </td>
                                 <td>4</td>
                                 <td>3</td>
                              </tr>
                              <tr>
                                 <td>
                                    <content styleCode="bold">NervousSystem</content>
                                 </td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                              </tr>
                              <tr>
                                 <td>Insomnia</td>
                                 <td>24</td>
                                 <td>13</td>
                                 <td>18</td>
                                 <td>10</td>
                                 <td>21</td>
                                 <td>16</td>
                              </tr>
                              <tr>
                                 <td>Somnolence</td>
                                 <td>24</td>
                                 <td>7</td>
                                 <td>19</td>
                                 <td>11</td>
                                 <td>22</td>
                                 <td>5</td>
                              </tr>
                              <tr>
                                 <td>Dizziness</td>
                                 <td>12</td>
                                 <td>6</td>
                                 <td>14</td>
                                 <td>10</td>
                                 <td>11</td>
                                 <td>7</td>
                              </tr>
                              <tr>
                                 <td>Tremor</td>
                                 <td>11</td>
                                 <td>1</td>
                                 <td>9</td>
                                 <td>1</td>
                                 <td>9</td>
                                 <td>1</td>
                              </tr>
                              <tr>
                                 <td>Nervousness</td>
                                 <td>9</td>
                                 <td>8</td>
                                 <td></td>
                                 <td></td>
                                 <td>8</td>
                                 <td>7</td>
                              </tr>
                              <tr>
                                 <td>LibidoDecreased</td>
                                 <td>7</td>
                                 <td>4</td>
                                 <td>9</td>
                                 <td>1</td>
                                 <td>12</td>
                                 <td>1</td>
                              </tr>
                              <tr>
                                 <td>Agitation</td>
                                 <td></td>
                                 <td></td>
                                 <td>5</td>
                                 <td>4</td>
                                 <td>3</td>
                                 <td>1</td>
                              </tr>
                              <tr>
                                 <td>Anxiety</td>
                                 <td></td>
                                 <td></td>
                                 <td>5</td>
                                 <td>4</td>
                                 <td>5</td>
                                 <td>4</td>
                              </tr>
                              <tr>
                                 <td>AbnormalDreams</td>
                                 <td>4</td>
                                 <td>1</td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                              </tr>
                              <tr>
                                 <td>Concentration</td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                              </tr>
                              <tr>
                                 <td>Impaired</td>
                                 <td>3</td>
                                 <td>2</td>
                                 <td></td>
                                 <td></td>
                                 <td>4</td>
                                 <td>1</td>
                              </tr>
                              <tr>
                                 <td>Depersonalization</td>
                                 <td>3</td>
                                 <td>0</td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                              </tr>
                              <tr>
                                 <td>Myoclonus</td>
                                 <td>3</td>
                                 <td>0</td>
                                 <td>3</td>
                                 <td>2</td>
                                 <td>2</td>
                                 <td>1</td>
                              </tr>
                              <tr>
                                 <td>Amnesia</td>
                                 <td>2</td>
                                 <td>1</td>
                                 <td>-</td>
                                 <td>-</td>
                                 <td>-</td>
                                 <td>-</td>
                              </tr>
                              <tr>
                                 <td>
                                    <content styleCode="bold">Respiratory</content>
                                 </td>
                                 <td rowspan="5">-</td>
                                 <td rowspan="5">-</td>
                                 <td rowspan="5">3</td>
                                 <td rowspan="5">0</td>
                                 <td colspan="2" rowspan="2"></td>
                              </tr>
                              <tr>
                                 <td rowspan="1">
                                    <content styleCode="bold">System</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td>Rhinitis</td>
                                 <td>-</td>
                                 <td>-</td>
                              </tr>
                              <tr>
                                 <td>Pharyngitis</td>
                                 <td>4</td>
                                 <td>2</td>
                              </tr>
                              <tr>
                                 <td>Yawn</td>
                                 <td>5</td>
                                 <td>1</td>
                              </tr>
                              <tr>
                                 <td>
                                    <content styleCode="bold">SpecialSenses</content>
                                 </td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                              </tr>
                              <tr>
                                 <td>AbnormalVision</td>
                                 <td>4</td>
                                 <td>2</td>
                                 <td></td>
                                 <td></td>
                                 <td>4</td>
                                 <td>1</td>
                              </tr>
                              <tr>
                                 <td>TastePerversion</td>
                                 <td>2</td>
                                 <td>0</td>
                                 <td>-</td>
                                 <td>-</td>
                                 <td>-</td>
                                 <td>-</td>
                              </tr>
                              <tr>
                                 <td>
                                    <content styleCode="bold">Urogenital</content>
                                 </td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                              </tr>
                              <tr>
                                 <td>
                                    <content styleCode="bold">System</content>
                                 </td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                              </tr>
                              <tr>
                                 <td>Abnormal</td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                              </tr>
                              <tr>
                                 <td>Ejaculation<sup>a</sup>
                                 </td>
                                 <td>23</td>
                                 <td>1</td>
                                 <td>21</td>
                                 <td>1</td>
                                 <td>28</td>
                                 <td>1</td>
                              </tr>
                              <tr>
                                 <td>Dysmenorrhea</td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td>5</td>
                                 <td rowspan="2">4</td>
                              </tr>
                              <tr>
                                 <td rowspan="2">FemaleGenital Disorder<sup>a</sup>
                                 </td>
                                 <td rowspan="2">3</td>
                                 <td rowspan="2">0</td>
                                 <td rowspan="2">9</td>
                                 <td rowspan="2">1</td>
                                 <td rowspan="2">9</td>
                              </tr>
                              <tr>
                                 <td>1</td>
                              </tr>
                              <tr>
                                 <td>Impotence<sup>a</sup>
                                 </td>
                                 <td>8</td>
                                 <td>1</td>
                                 <td>5</td>
                                 <td>0</td>
                                 <td>5</td>
                                 <td>1</td>
                              </tr>
                              <tr>
                                 <td>Urinary</td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                              </tr>
                              <tr>
                                 <td>Frequency</td>
                                 <td>3</td>
                                 <td>1</td>
                                 <td>2</td>
                                 <td>0</td>
                                 <td></td>
                                 <td></td>
                              </tr>
                              <tr>
                                 <td>Urination</td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                              </tr>
                              <tr>
                                 <td>Impaired</td>
                                 <td>3</td>
                                 <td>0</td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                              </tr>
                              <tr>
                                 <td rowspan="2">UrinaryTract Infection</td>
                                 <td rowspan="2">2</td>
                                 <td rowspan="2">1</td>
                                 <td rowspan="2">2</td>
                                 <td rowspan="2">1</td>
                                 <td rowspan="2"></td>
                                 <td></td>
                              </tr>
                              <tr>
                                 <td rowspan="1"></td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph> a. Percentagecorrectedforgender.</paragraph>
                        <paragraph>
                           <content styleCode="underline">AdverseReactionsinPatientswithGADandPTSD</content>
                        </paragraph>
                        <paragraph>Table 6 presents adverse reactions that occurred at a frequency of 2% or more in clinical trials inpatientswithGADandPTSD.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 6. Adverse Reactions (2% of Paroxetine-Treated Patients and Greater than Placebo) in8-to 12-Week Clinical Trials for GAD and PTSD<sup>a</sup>
                           </content>
                        </paragraph>
                        <table frame="border" rules="all">
                           <tbody>
                              <tr>
                                 <td rowspan="2">
                                    <content styleCode="bold">Body</content>
                                    <content styleCode="bold">System/Preferred Term</content>
                                 </td>
                                 <td colspan="2">
                                    <content styleCode="bold">Generalized AnxietyDisorder</content>
                                 </td>
                                 <td colspan="2">
                                    <content styleCode="bold">Posttraumatic StressDisorder</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" valign="top">
                                    <content styleCode="bold">Paroxetine <br/></content>
                                    <content styleCode="bold">(n=735)</content>
                                    <content styleCode="bold">
                                       <br/>%</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="bold">Placebo</content>
                                    <br/>
                                    <content styleCode="bold">(n=529)</content>
                                    <br/>
                                    <content styleCode="bold">%</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="bold">Paroxetine<br/> (n=676)</content>
                                    <br/>
                                    <content styleCode="bold">%</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="bold">Placebo<br/>
                                    </content>
                                    <content styleCode="bold">(n=504)</content>
                                    <content styleCode="bold">
                                       <br/>%</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td>
                                    <content styleCode="bold">Bodyasa Whole</content>
                                 </td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                              </tr>
                              <tr>
                                 <td>Asthenia</td>
                                 <td>14</td>
                                 <td>6</td>
                                 <td>12</td>
                                 <td>4</td>
                              </tr>
                              <tr>
                                 <td>Headache</td>
                                 <td>17</td>
                                 <td>14</td>
                                 <td></td>
                                 <td></td>
                              </tr>
                              <tr>
                                 <td>Infection</td>
                                 <td>6</td>
                                 <td>3</td>
                                 <td>5</td>
                                 <td>4</td>
                              </tr>
                              <tr>
                                 <td>AbdominalPain</td>
                                 <td></td>
                                 <td></td>
                                 <td>4</td>
                                 <td>3</td>
                              </tr>
                              <tr>
                                 <td>Trauma</td>
                                 <td></td>
                                 <td></td>
                                 <td>6</td>
                                 <td>5</td>
                              </tr>
                              <tr>
                                 <td>
                                    <content styleCode="bold">Cardiovascular <br/>
                                    </content>Vasodilation</td>
                                 <td>
                                    <content styleCode="bold"></content>3</td>
                                 <td>
                                    <content styleCode="bold"></content>1</td>
                                 <td>
                                    <content styleCode="bold"></content>2</td>
                                 <td>
                                    <content styleCode="bold"></content>1</td>
                              </tr>
                              <tr>
                                 <td>
                                    <content styleCode="bold">Dermatologic</content>
                                    <br/>Sweating</td>
                                 <td>
                                    <content styleCode="bold"></content>6</td>
                                 <td>
                                    <content styleCode="bold"></content>2</td>
                                 <td>
                                    <content styleCode="bold"></content>5</td>
                                 <td>
                                    <content styleCode="bold"></content>1</td>
                              </tr>
                              <tr>
                                 <td>
                                    <content styleCode="bold">Gastrointestinal</content>
                                 </td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                              </tr>
                              <tr>
                                 <td>Nausea</td>
                                 <td>20</td>
                                 <td>5</td>
                                 <td>19</td>
                                 <td>8</td>
                              </tr>
                              <tr>
                                 <td>DryMouth</td>
                                 <td>11</td>
                                 <td>5</td>
                                 <td>10</td>
                                 <td>5</td>
                              </tr>
                              <tr>
                                 <td>Constipation</td>
                                 <td>10</td>
                                 <td>2</td>
                                 <td>5</td>
                                 <td>3</td>
                              </tr>
                              <tr>
                                 <td>Diarrhea</td>
                                 <td>9</td>
                                 <td>7</td>
                                 <td>11</td>
                                 <td>5</td>
                              </tr>
                              <tr>
                                 <td>Decreased</td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                              </tr>
                              <tr>
                                 <td>Appetite</td>
                                 <td>5</td>
                                 <td>1</td>
                                 <td>6</td>
                                 <td>3</td>
                              </tr>
                              <tr>
                                 <td>Vomiting</td>
                                 <td>3</td>
                                 <td>2</td>
                                 <td>3</td>
                                 <td>2</td>
                              </tr>
                              <tr>
                                 <td>Dyspepsia</td>
                                 <td></td>
                                 <td></td>
                                 <td>5</td>
                                 <td>3</td>
                              </tr>
                              <tr>
                                 <td>
                                    <content styleCode="bold">Nervous System</content>
                                 </td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                              </tr>
                              <tr>
                                 <td>Insomnia</td>
                                 <td>11</td>
                                 <td>8</td>
                                 <td>12</td>
                                 <td>11</td>
                              </tr>
                              <tr>
                                 <td>Somnolence</td>
                                 <td>15</td>
                                 <td>5</td>
                                 <td>16</td>
                                 <td>5</td>
                              </tr>
                              <tr>
                                 <td>Dizziness</td>
                                 <td>6</td>
                                 <td>5</td>
                                 <td>6</td>
                                 <td>5</td>
                              </tr>
                              <tr>
                                 <td>Tremor</td>
                                 <td>5</td>
                                 <td>1</td>
                                 <td>4</td>
                                 <td>1</td>
                              </tr>
                              <tr>
                                 <td>Nervousness</td>
                                 <td>4</td>
                                 <td>3</td>
                                 <td>-</td>
                                 <td>-</td>
                              </tr>
                              <tr>
                                 <td>Libido Decreased</td>
                                 <td>9</td>
                                 <td>2</td>
                                 <td>5</td>
                                 <td>2</td>
                              </tr>
                              <tr>
                                 <td>Abnormal Dreams</td>
                                 <td>-</td>
                                 <td>-</td>
                                 <td>3</td>
                                 <td>-</td>
                              </tr>
                              <tr>
                                 <td>
                                    <content styleCode="bold">Respiratory System</content>
                                 </td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                              </tr>
                              <tr>
                                 <td>Respiratory Disorder</td>
                                 <td>7</td>
                                 <td>5</td>
                                 <td>-</td>
                                 <td>-</td>
                              </tr>
                              <tr>
                                 <td>Sinusitis</td>
                                 <td>4</td>
                                 <td>3</td>
                                 <td>-</td>
                                 <td>-</td>
                              </tr>
                              <tr>
                                 <td>Yawn</td>
                                 <td>4</td>
                                 <td>-</td>
                                 <td>2</td>
                                 <td>1</td>
                              </tr>
                              <tr>
                                 <td>
                                    <content styleCode="bold">Special Senses</content>
                                 </td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                              </tr>
                              <tr>
                                 <td>Abnormal Vision</td>
                                 <td>2</td>
                                 <td>1</td>
                                 <td>3</td>
                                 <td>1</td>
                              </tr>
                              <tr>
                                 <td>
                                    <content styleCode="bold">Urogenital System</content>
                                 </td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                                 <td></td>
                              </tr>
                              <tr>
                                 <td>Abnormal Ejaculation <sup>a</sup>
                                 </td>
                                 <td>25</td>
                                 <td>2</td>
                                 <td>13</td>
                                 <td>2</td>
                              </tr>
                              <tr>
                                 <td>Female Genital Disorder <sup>a</sup>
                                 </td>
                                 <td>4</td>
                                 <td>1</td>
                                 <td>5</td>
                                 <td>1</td>
                              </tr>
                              <tr>
                                 <td>Impotence <sup>a</sup>
                                 </td>
                                 <td>4</td>
                                 <td>3</td>
                                 <td>9</td>
                                 <td>1</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <sup>a.</sup>Percentagecorrectedforgender.</paragraph>
                        <paragraph>
                           <content styleCode="underline">DoseDependentAdverseReactions</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">MDD</content>
                           <content styleCode="underline"/>
                        </paragraph>
                        <paragraph>A comparison of adverse reaction rates in a fixed-dose study comparing paroxetine 10 mg, 20 mg,30 mg, and 40 mg once daily with placebo in the treatment of MDD revealed dose dependentadversereactions, as shownin Table 7:</paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 7. Adverse Reactions (5% of Paroxetine -Treated Patients and  Twice the Rate of Placebo)(ina Dose-Comparison Trial</content>
                           <content styleCode="bold"> in the Treatment of MDD</content>
                        </paragraph>
                        <table frame="border" rules="all">
                           <tbody>
                              <tr>
                                 <td rowspan="4">
                                    <content styleCode="bold">BodySystem/PreferredTerm</content>
                                 </td>
                                 <td align="center" rowspan="4">
                                    <content styleCode="bold">Placebo</content> <br/>
                                    <content styleCode="bold">n = 51</content>
                                    <content styleCode="bold">
                                       <br/>%</content>
                                 </td>
                                 <td align="center" colspan="7" valign="middle">
                                    <content styleCode="bold">Paroxetine </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td>
                                    <content styleCode="bold">10 mg</content>
                                 </td>
                                 <td colspan="3">
                                    <content styleCode="bold">20 mg</content>
                                 </td>
                                 <td colspan="2">
                                    <content styleCode="bold">30 mg</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">40 mg</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td>
                                    <content styleCode="bold">n = 102</content>
                                 </td>
                                 <td colspan="3">
                                    <content styleCode="bold">n = 104</content>
                                 </td>
                                 <td colspan="2">
                                    <content styleCode="bold">n = 101</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">n = 102</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td>
                                    <content styleCode="bold">%</content>
                                 </td>
                                 <td colspan="3">
                                    <content styleCode="bold">%</content>
                                 </td>
                                 <td colspan="2">
                                    <content styleCode="bold">%</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">%</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td>
                                    <content styleCode="bold">BodyasaWhole</content>
                                    <br/>Asthenia </td>
                                 <td>  0 </td>
                                 <td colspan="2">  2.9 </td>
                                 <td>  10.6 </td>
                                 <td colspan="2">  13.9 </td>
                                 <td colspan="2">  12.7 </td>
                              </tr>
                              <tr>
                                 <td>
                                    <content styleCode="bold">Dermatology</content>
                                    <br/> Sweating </td>
                                 <td>  2 </td>
                                 <td colspan="2">  1 </td>
                                 <td>  6.7 </td>
                                 <td colspan="2">  8.9 </td>
                                 <td colspan="2">  11.8 </td>
                              </tr>
                              <tr>
                                 <td>
                                    <content styleCode="bold">Gastrointestinal</content>
                                 </td>
                                 <td>  </td>
                                 <td colspan="2">  </td>
                                 <td>  </td>
                                 <td colspan="2">  </td>
                                 <td colspan="2">  </td>
                              </tr>
                              <tr>
                                 <td> Constipation </td>
                                 <td> 5.9 </td>
                                 <td colspan="2"> 4.9 </td>
                                 <td> 7.7 </td>
                                 <td colspan="2"> 9.9 </td>
                                 <td colspan="2"> 12.7 </td>
                              </tr>
                              <tr>
                                 <td> DecreasedAppetite </td>
                                 <td> 2 </td>
                                 <td colspan="2"> 2 </td>
                                 <td> 5.8 </td>
                                 <td colspan="2"> 4 </td>
                                 <td colspan="2"> 4.9 </td>
                              </tr>
                              <tr>
                                 <td> Diarrhea </td>
                                 <td> 7.8 </td>
                                 <td colspan="2"> 9.8 </td>
                                 <td> 19.2 </td>
                                 <td colspan="2"> 7.9 </td>
                                 <td colspan="2"> 14.7 </td>
                              </tr>
                              <tr>
                                 <td> DryMouth </td>
                                 <td> 2 </td>
                                 <td colspan="2"> 10.8 </td>
                                 <td> 18.3 </td>
                                 <td colspan="2"> 15.8 </td>
                                 <td colspan="2"> 20.6 </td>
                              </tr>
                              <tr>
                                 <td> Nausea </td>
                                 <td> 13.7 </td>
                                 <td colspan="2"> 14.7 </td>
                                 <td> 26.9 </td>
                                 <td colspan="2"> 34.7 </td>
                                 <td colspan="2"> 36.3 </td>
                              </tr>
                              <tr>
                                 <td>
                                    <content styleCode="bold">Nervous System</content>
                                 </td>
                                 <td>  </td>
                                 <td colspan="2">  </td>
                                 <td>  </td>
                                 <td colspan="2">  </td>
                                 <td colspan="2">  </td>
                              </tr>
                              <tr>
                                 <td> Anxiety </td>
                                 <td> 0 </td>
                                 <td colspan="2"> 2. </td>
                                 <td> 5.8 </td>
                                 <td colspan="2"> 5.9 </td>
                                 <td colspan="2"> 5.9 </td>
                              </tr>
                              <tr>
                                 <td> Dizziness </td>
                                 <td> 3.9 </td>
                                 <td colspan="2"> 6.9 </td>
                                 <td> 6.7 </td>
                                 <td colspan="2"> 8.9 </td>
                                 <td colspan="2"> 12.7 </td>
                              </tr>
                              <tr>
                                 <td> Nervousness </td>
                                 <td> 0 </td>
                                 <td colspan="2"> 5.9 </td>
                                 <td> 5.8 </td>
                                 <td colspan="2"> 4 </td>
                                 <td colspan="2"> 2.9 </td>
                              </tr>
                              <tr>
                                 <td> Paresthesia </td>
                                 <td> 0 </td>
                                 <td colspan="2"> 2.9 </td>
                                 <td> 1 </td>
                                 <td colspan="2"> 5 </td>
                                 <td colspan="2"> 5.9 </td>
                              </tr>
                              <tr>
                                 <td> Somnolence </td>
                                 <td> 7.8 </td>
                                 <td colspan="2"> 12.7 </td>
                                 <td> 18.3 </td>
                                 <td colspan="2"> 20.8 </td>
                                 <td colspan="2"> 21.6 </td>
                              </tr>
                              <tr>
                                 <td> Tremor </td>
                                 <td> 0 </td>
                                 <td colspan="2"> 0 </td>
                                 <td> 7.7 </td>
                                 <td colspan="2"> 7.9 </td>
                                 <td colspan="2"> 14.7 </td>
                              </tr>
                              <tr>
                                 <td>
                                    <content styleCode="bold">SpecialSenses</content>
                                    <br/>BlurredVision </td>
                                 <td>  2 </td>
                                 <td colspan="2">  2.9 </td>
                                 <td>  2.9 </td>
                                 <td colspan="2">  2 </td>
                                 <td colspan="2">  7.8 </td>
                              </tr>
                              <tr>
                                 <td>
                                    <content styleCode="bold">Urogenital System</content>
                                 </td>
                                 <td>  </td>
                                 <td colspan="2">  </td>
                                 <td>  </td>
                                 <td colspan="2">  </td>
                                 <td colspan="2">  </td>
                              </tr>
                              <tr>
                                 <td> AbnormalEjaculation </td>
                                 <td> 0 </td>
                                 <td colspan="2"> 5.8 </td>
                                 <td> 6.5 </td>
                                 <td colspan="2"> 10.6 </td>
                                 <td colspan="2"> 13 </td>
                              </tr>
                              <tr>
                                 <td> Impotence </td>
                                 <td> 0 </td>
                                 <td colspan="2"> 1.9 </td>
                                 <td> 4.3 </td>
                                 <td colspan="2"> 6.4 </td>
                                 <td colspan="2"> 1.9 </td>
                              </tr>
                              <tr>
                                 <td> MaleGenitalDisorders </td>
                                 <td> 0 </td>
                                 <td colspan="2"> 3.8 </td>
                                 <td> 8.7 </td>
                                 <td colspan="2"> 6.4 </td>
                                 <td colspan="2"> 3.7 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="italics">OCD</content>
                        </paragraph>
                        <paragraph>In a fixed-dose study comparing placebo and paroxetine 20 mg, 40 mg, and 60 mg in the treatmentof OCD, there was no clear relationship between adverse reactions and the dose of paroxetine towhichpatients wereassigned.</paragraph>
                        <paragraph>
                           <content styleCode="italics">PD</content>
                        </paragraph>
                        <paragraph>In a fixed-dose study comparing placebo and paroxetine 10 mg, 20 mg, and 40 mg in the treatmentof PD, the following adverse reactions were shown to be dose-dependent: asthenia, dry mouth,anxiety,libido decreased, tremor, and abnormal ejaculation.</paragraph>
                        <paragraph>
                           <content styleCode="italics">SAD</content>
                        </paragraph>
                        <paragraph>In a fixed-dose study comparing placebo and paroxetine 20 mg, 40 mg and 60 mg in the treatmentof SAD, for most of the adverse reactions, there was no clear relationship between adversereactionsand the dose of paroxetineto whichpatients wereassigned.</paragraph>
                        <paragraph>
                           <content styleCode="italics">GAD</content>
                        </paragraph>
                        <paragraph>Inafixed-dosestudycomparingplaceboandparoxetine 20mgand40mginthe treatmentofGAD,the following adverse reactions were shown to be dose-dependent: asthenia, constipation, andabnormalejaculation.</paragraph>
                        <paragraph>
                           <content styleCode="italics">PTSD</content>
                        </paragraph>
                        <paragraph>In a fixed-dose study comparing placebo and paroxetine 20 mg and 40 mg in the treatment of PTSD,the following adverse reactions were shown to be dose-dependent: impotence and abnormalejaculation.</paragraph>
                        <paragraph>
                           <content styleCode="underline">MaleandFemaleSexualDysfunction</content>
                        </paragraph>
                        <paragraph>Although changes in sexual desire, sexual performance, and sexual satisfaction often occur asmanifestations of a psychiatric disorder, they may also be a consequence of SSRI treatment.However, reliable estimates of the incidence and severity of untoward experiences involvingsexual desire, performance, and satisfaction are difficult to obtain, however, in part becausepatients and healthcare providers may be reluctant to discuss them. Accordingly, estimates of theincidence of untoward sexual experience and performance cited in labeling may underestimatetheiractualincidence.The percentage of patients reporting symptoms of sexual dysfunction in males and females withMDD,OCD,PD,SAD,GAD,and PTSDaredisplayed in Table 8.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 8. Adverse Reactions Related to Sexual Dysfunction in Patients Treated with Paroxetine inClinicalTrialsofMDD,OCD,PD, SAD,GAD, and PTSD</content>
                        </paragraph>
                        <table frame="border" rules="all">
                           <tbody>
                              <tr>
                                 <td></td>
                                 <td>
                                    <content styleCode="bold">Paroxetine</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">Placebo</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td>
                                    <content styleCode="bold">n(males)</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">1,446</content>
                                    <content styleCode="bold">
                                       <br/>%</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">1,042</content>
                                    <content styleCode="bold">
                                       <br/>%</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td>DecreasedLibido</td>
                                 <td>6 to15</td>
                                 <td>0 to 5</td>
                              </tr>
                              <tr>
                                 <td>EjaculatoryDisturbance</td>
                                 <td>13to28</td>
                                 <td>0 to2</td>
                              </tr>
                              <tr>
                                 <td>Impotence</td>
                                 <td>2 to 9</td>
                                 <td>0 to 3</td>
                              </tr>
                              <tr>
                                 <td>
                                    <content styleCode="bold">n(females)</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">1,822</content>
                                    <content styleCode="bold">
                                       <br/>%</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">1,340</content>
                                    <br/>
                                    <content styleCode="bold">%</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td>DecreasedLibido</td>
                                 <td>0 to 9</td>
                                 <td>0 to 2</td>
                              </tr>
                              <tr>
                                 <td>OrgasmicDisturbance</td>
                                 <td>2 to 9</td>
                                 <td>0 to 1</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Paroxetine treatment has been associated with several cases of priapism. In those cases with aknownoutcome, patients recoveredwithoutsequelae.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Hallucinations</content>
                        </paragraph>
                        <paragraph>In pooled clinical trials of paroxetine, hallucinations were observed in 0.2% of paroxetine-treated patientscompared to 0.1% of patientsreceiving placebo.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Less Common AdverseReactions</content>
                        </paragraph>
                        <paragraph>The following adverse reactions occurred during the clinical studies of paroxetine and are notincluded elsewhere in the labeling.</paragraph>
                        <paragraph>Adverse reactionsare categorized by body system and listed in order of decreasing frequencyaccording to the following definitions: Frequent adverse reactions are those occurring on 1 ormore occasions in at least 1/100 patients; infrequent adverse reactions are those occurring in1/100 to 1/1,000 patients; rare adverse reactions are those occurring in fewer than 1/1,000patients.</paragraph>
                        <paragraph>
                           <content styleCode="italics">BodyasaWhole</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Infrequent:</content>Allergicreaction,chills,faceedema,malaise,neckpain;<content styleCode="italics">rare:</content>Adrenergicsyndrome,cellulitis,moniliasis, neckrigidity, pelvicpain, peritonitis,sepsis,ulcer.</paragraph>
                        <paragraph>
                           <content styleCode="italics">CardiovascularSystem</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics"/>
                           <content styleCode="italics">Frequent:</content> Hypertension, tachycardia; infrequent: Bradycardia, hematoma, hypotension,migraine, postural hypotension, syncope; <content styleCode="italics">rare:</content> Angina pectoris, arrhythmia nodal, atrialfibrillation, bundle branch block, cerebral ischemia, cerebrovascular accident, congestive heartfailure,heart block, lowcardiacoutput, myocardialinfarct, myocardial ischemia, pallor, phlebitis, pulmonary embolus, supraventricular extrasystoles, thrombophlebitis, thrombosis,varicosevein, vascular headache, ventricular extrasystoles.</paragraph>
                        <paragraph>
                           <content styleCode="italics">DigestiveSystem</content>
                           <content styleCode="italics"/>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Infrequent:</content> Bruxism, colitis, dysphagia, eructation, gastritis, gastroenteritis, gingivitis, glossitis,increased salivation, abnormal liver function tests, rectal hemorrhage, ulcerative stomatitis; <content styleCode="italics">rare:</content>Aphthous stomatitis, bloody diarrhea, bulimia, cardiospasm, cholelithiasis, duodenitis, enteritis,esophagitis, fecal impactions, fecal incontinence, gum hemorrhage, hematemesis, hepatitis,ileitis, ileus, intestinal obstruction, jaundice, melena, mouth ulceration, peptic ulcer, salivarygland enlargement, sialadenitis, stomach ulcer, stomatitis, tongue discoloration, tongue edema,toothcaries.</paragraph>
                        <paragraph>
                           <content styleCode="italics">EndocrineSystem</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Rare:</content>Diabetesmellitus,goiter,hyperthyroidism,hypothyroidism,thyroiditis.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Hemicand Lymphatic Systems</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Infrequent:</content> Anemia, leukopenia, lymphadenopathy, purpura; <content styleCode="italics">rare:</content> Abnormal erythrocytes,basophilia, bleeding time increased, eosinophilia, hypochromic anemia, iron deficiency anemia,leukocytosis, lymphedema, abnormal lymphocytes, lymphocytosis, microcytic anemia,monocytosis,normocytic anemia,thrombocythemia, thrombocytopenia.</paragraph>
                        <paragraph>
                           <content styleCode="italics">MetabolicandNutritional</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Frequent:</content> Weight gain; <content styleCode="italics">infrequent:</content> Edema, peripheral edema, SGOT increased, SGPT increased,thirst, weight loss;<content styleCode="italics"> rare:</content> Alkaline phosphatase increased, bilirubinemia, BUN increased,creatinine phosphokinase increased, dehydration, gamma globulins increased, gout,hypercalcemia, hypercholesteremia, hyperglycemia, hyperkalemia, hyperphosphatemia,hypocalcemia, hypoglycemia, hypokalemia, hyponatremia, ketosis, lactic dehydrogenaseincreased,non-protein nitrogen(NPN)increased.</paragraph>
                        <paragraph>
                           <content styleCode="italics">MusculoskeletalSystem</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Frequent:</content> Arthralgia; <content styleCode="italics">infrequent:</content> Arthritis, arthrosis;<content styleCode="italics"> rare:</content> Bursitis, myositis, osteoporosis,generalizedspasm, tenosynovitis,tetany.</paragraph>
                        <paragraph>
                           <content styleCode="italics">NervousSystem</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Frequent:</content> Emotional lability, vertigo; <content styleCode="italics">infrequent:</content> Abnormal thinking, alcohol abuse, ataxia,dystonia, dyskinesia, euphoria, hostility, hypertonia, hypesthesia, hypokinesia, incoordination,lack of emotion, libido increased, manic reaction, neurosis, paralysis, paranoid reaction; <content styleCode="italics">rare:</content>Abnormal gait, akinesia, antisocial reaction, aphasia, choreoathetosis, circumoral paresthesias,convulsion, delirium, delusions, diplopia, drug dependence, dysarthria, extrapyramidalsyndrome,fasciculations, grandmal convulsion,hyperalgesia, hysteria,manic-depressive reaction, meningitis, myelitis, neuralgia, neuropathy, nystagmus, peripheral neuritis, psychoticdepression, psychosis, reflexes decreased, reflexes increased, stupor, torticollis, trismus,withdrawalsyndrome.</paragraph>
                        <paragraph>
                           <content styleCode="italics">RespiratorySystem</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Infrequent: </content>Asthma, bronchitis, dyspnea, epistaxis, hyperventilation, pneumonia, respiratory flu;<content styleCode="italics">rare:</content> Emphysema, hemoptysis, hiccups, lung fibrosis, pulmonary edema, sputum increased,stridor,voicealteration.</paragraph>
                        <paragraph>
                           <content styleCode="italics">SkinandAppendages</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Frequent:</content>Pruritus;<content styleCode="italics">infrequent:</content>Acne,alopecia,contactdermatitis,dryskin,ecchymosis,eczema,herpes simplex, photosensitivity, urticaria; <content styleCode="italics">rare:</content> Angioedema, erythema nodosum, erythemamultiforme, exfoliative dermatitis, fungal dermatitis, furunculosis; herpes zoster, hirsutism,maculopapular rash, seborrhea, skin discoloration, skin hypertrophy, skin ulcer, sweatingdecreased, vesiculobullous rash.</paragraph>
                        <paragraph>
                           <content styleCode="italics">SpecialSenses</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Frequent:</content> Tinnitus; <content styleCode="italics">infrequent:</content> Abnormality of accommodation, conjunctivitis, ear pain, eyepain, keratoconjunctivitis, mydriasis, otitis media; <content styleCode="italics">rare:</content> Amblyopia, anisocoria, blepharitis,cataract, conjunctival edema, corneal ulcer, deafness, exophthalmos, eye hemorrhage, glaucoma,hyperacusis, night blindness, otitis externa, parosmia, photophobia, ptosis, retinal hemorrhage,tasteloss, visualfielddefect.</paragraph>
                        <paragraph>
                           <content styleCode="italics">UrogenitalSystem</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Infrequent:</content> Amenorrhea, breast pain, cystitis, dysuria, hematuria, menorrhagia, nocturia,polyuria, pyuria, urinary incontinence, urinary retention, urinary urgency, vaginitis; <content styleCode="italics">rare:</content>Abortion, breast atrophy, breast enlargement, endometrial disorder, epididymitis, femalelactation, fibrocystic breast, kidney calculus, kidney pain, leukorrhea, mastitis, metrorrhagia,nephritis, oliguria, salpingitis, urethritis, urinary casts, uterine spasm, urolith, vaginalhemorrhage,vaginal moniliasis.</paragraph>
                        <paragraph>
                           <content styleCode="italics"/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250103"/>
                  </section>
               </component>
               <component>
                  <section ID="_7cdda414-e252-f29d-b546-6e7e402769b7">
                     <id root="3d592211-5187-5b47-939c-3f6dd9b1bb95"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>6.2 Postmarketing Experience</title>
                     <text>
                        <paragraph>The following reactions have been identified during post approval use of paroxetine. Because thesereactions are reported voluntarily from a population of unknown size, it is not always possible toreliablyestimatetheirfrequencyorestablishacausalrelationshiptodrugexposure.</paragraph>
                        <paragraph>Acute pancreatitis, elevated liver function tests (the most severe cases were deaths due to livernecrosis, and grossly elevated transaminases associated with severe liver dysfunction),Guillain-Barr syndrome, Stevens-Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms (DRESS), syndrome ofinappropriateADHsecretion,prolactinemiaandgalactorrhea;extrapyramidalsymptomswhich have included akathisia, bradykinesia, cogwheel rigidity, oculogyric crisis which has beenassociated with concomitant use of pimozide; status epilepticus, acute renal failure, pulmonaryhypertension, allergic alveolitis, anosmia, hyposmia, anaphylaxis, eclampsia, laryngismus, optic neuritis, porphyria,restless legs syndrome (RLS), ventricular fibrillation, ventricular tachycardia (including torsadede pointes), hemolytic anemia, events related to impaired hematopoiesis (including aplasticanemia, pancytopenia, bone marrow aplasia, and agranulocytosis), vasculitic syndromes (such asHenoch-Schnlein purpura), and premature births in pregnant women. There has been a casereportofseverehypotensionwhenparoxetinewasaddedto chronicmetoprololtreatment.</paragraph>
                     </text>
                     <effectiveTime value="20230912"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="_98fb8324-731b-1e24-7f26-087b47024334">
               <id root="e72e1b66-8c4e-c5b1-7afb-2e4b362ff345"/>
               <code code="34073-7" displayName="DRUG INTERACTIONS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>7 DRUG INTERACTIONS</title>
               <text>
                  <paragraph>Table9presentsclinicallysignificantdruginteractionswithparoxetine.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Table9:ClinicallySignificantDrugInteractionswithParoxetine</content>
                  </paragraph>
                  <table frame="box" rules="all">
                     <tbody>
                        <tr>
                           <td colspan="3">
                              <content styleCode="bold">Monoamine Oxidase Inhibitors (MAOIs)</content>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <content styleCode="italics"> ClinicalImpact</content>
                           </td>
                           <td colspan="2"> The concomitant use of SSRIs, including paroxetine, and MAOIs increases theriskofserotonin syndrome. </td>
                        </tr>
                        <tr>
                           <td>
                              <content styleCode="italics"> Intervention</content>
                           </td>
                           <td colspan="2"> Paroxetineiscontraindicatedinpatientstaking MAOIs,includingMAOIs suchaslinezolidorintravenousmethyleneblue<content styleCode="italics">[seeDosage andAdministration(<linkHtml href="#_4bfa2214-2145-6513-ebb8-8373f6763bb4">2.5</linkHtml>), Contraindications(<linkHtml href="#_321b7fb7-47b4-cee3-aaa7-fdbac8de2624">4</linkHtml>),WarningsandPrecautions (<linkHtml href="#_cc482d0a-c6f1-da5a-37db-cf01b70fbb16">5.2</linkHtml>)]. </content>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <content styleCode="italics"> Examples</content>
                           </td>
                           <td colspan="2"> selegiline,tranylcypromine,isocarboxazid,phenelzine,linezolid,methyleneblue </td>
                        </tr>
                        <tr>
                           <td colspan="3">
                              <content styleCode="bold">PimozideandThioridazine</content>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <content styleCode="italics"> ClinicalImpact</content>
                           </td>
                           <td colspan="2"> Increasedplasmaconcentrationsofpimozideandthioridazine,drugs withanarrowtherapeuticindex,mayincreasetheriskofQTcprolongationand ventriculararrhythmias. </td>
                        </tr>
                        <tr>
                           <td>
                              <content styleCode="italics"> Intervention</content>
                           </td>
                           <td colspan="2"> Paroxetine iscontraindicatedinpatientstaking pimozideorthioridazine <content styleCode="italics"> [seeContraindications(<linkHtml href="#_321b7fb7-47b4-cee3-aaa7-fdbac8de2624">4</linkHtml>)]. </content>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3">
                              <content styleCode="bold">OtherSerotonergicDrugs</content>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <content styleCode="italics">ClinicalImpact</content>
                           </td>
                           <td colspan="2"> Theconcomitantuseofserotonergicdrugs withparoxetineincreasestheriskof serotoninsyndrome. </td>
                        </tr>
                        <tr>
                           <td>
                              <content styleCode="italics"> Intervention</content>
                           </td>
                           <td colspan="2"> Monitor patients for signs and symptoms of serotonin syndrome, particularly during treatment initiation and dosage increases. If serotonin syndrome occurs,considerdiscontinuationofparoxetineand/or concomitantserotonergicdrugs <content styleCode="italics"> [see WarningsandPrecautions(<linkHtml href="#_cc482d0a-c6f1-da5a-37db-cf01b70fbb16">5.2</linkHtml>)]</content>. </td>
                        </tr>
                        <tr>
                           <td>
                              <content styleCode="italics"> Examples</content>
                           </td>
                           <td colspan="2"> otherSSRIs,SNRIs,triptans,tricyclicantidepressants,opioids, lithium, tryptophan, buspirone, amphetamines, and St.JohnsWort.</td>
                        </tr>
                        <tr>
                           <td colspan="3">
                              <content styleCode="bold">DrugsthatInterferewith Hemostasis(antiplateletagents andanticoagulants)</content>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2">
                              <content styleCode="italics"> ClinicalImpact</content>
                           </td>
                           <td> The concurrent use of an antiplatelet agent or anticoagulant with paroxetinemay potentiate the risk of bleeding. </td>
                        </tr>
                        <tr>
                           <td colspan="2">
                              <content styleCode="italics"> Intervention</content>
                           </td>
                           <td> Inform patients of the increased risk of bleeding associated with the concomitant use of paroxetine and antiplatelet agents and anticoagulants. For patients taking warfarin, carefully monitor the international normalized ratio <content styleCode="italics"> [see Warnings and Precautions (<linkHtml href="#_653d03c0-3732-f4ff-cd4d-3f78936c5075">5.5</linkHtml>)]. </content>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2">
                              <content styleCode="italics"> Examples</content>
                           </td>
                           <td> aspirin, clopidogrel, heparin, warfarin </td>
                        </tr>
                        <tr>
                           <td colspan="3">
                              <content styleCode="bold">Drugs Highly Bound to Plasma Protein </content>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2">
                              <content styleCode="italics">Clinical Impact</content>
                           </td>
                           <td> Paroxetine is highly bound to plasma protein. The concomitant use of paroxetine with another drug that is highly bound to plasma protein may increase free concentrations of paroxetine or other tightly-bound drugs in plasma. </td>
                        </tr>
                        <tr>
                           <td colspan="2">
                              <content styleCode="italics"> Intervention</content>
                           </td>
                           <td> Monitor for adverse reactions and reduce dosage of paroxetine or other protein-bound drugs as warranted. </td>
                        </tr>
                        <tr>
                           <td colspan="2">
                              <content styleCode="italics"> Examples</content>
                           </td>
                           <td> Warfarin </td>
                        </tr>
                        <tr>
                           <td colspan="3">
                              <content styleCode="bold">DrugsMetabolizedbyCYP2D6</content>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2">
                              <content styleCode="italics"> ClinicalImpact</content>
                           </td>
                           <td> ParoxetineisaCYP2D6 inhibitor<content styleCode="italics">[seeClinicalPharmacology(<linkHtml href="#_5511a139-d401-10fa-8008-50c47873c7b7">12.3</linkHtml>)].</content>The concomitantuseofparoxetinewithaCYP2D6 substratemayincreasetheexposureoftheCYP2D6 substrate. </td>
                        </tr>
                        <tr>
                           <td colspan="2">
                              <content styleCode="italics"> Intervention</content>
                           </td>
                           <td> Decreasethe dosageofaCYP2D6substrateifneededwith concomitantparoxetine use. Conversely, an increase in dosage of a CYP2D6 substratemaybeneeded ifparoxetineisdiscontinued. </td>
                        </tr>
                        <tr>
                           <td colspan="2">
                              <content styleCode="italics">Examples </content>
                           </td>
                           <td> propafenone, flecainide, atomoxetine, desipramine, dextromethorphan, metoprolol,nebivolol,perphenazine,tolterodine,venlafaxine,risperidone. </td>
                        </tr>
                        <tr>
                           <td colspan="3">
                              <content styleCode="bold">Tamoxifen</content>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2">
                              <content styleCode="italics">ClinicalImpact</content>
                           </td>
                           <td> Concomitant use of tamoxifen with paroxetine may lead to reduced plasmaconcentrationsoftheactive metabolite(endoxifen)andreducedefficacy oftamoxifen </td>
                        </tr>
                        <tr>
                           <td colspan="2">
                              <content styleCode="italics"> Intervention</content>
                           </td>
                           <td> ConsideruseofanalternativeantidepressantwithlittleornoCYP2D6inhibition<content styleCode="italics">[seeWarningsandPrecautions(<linkHtml href="#_128b39fe-9a39-3ec7-99a3-672ce8d35f3d">5.11</linkHtml>)].</content>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3">
                              <content styleCode="bold">Fosamprenavir/Ritonavir</content>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2">
                              <content styleCode="italics">ClinicalImpact </content>
                           </td>
                           <td> Co-administrationoffosamprenavir/ritonavirwith paroxetinesignificantlydecreasedplasmalevels ofparoxetine. </td>
                        </tr>
                        <tr>
                           <td colspan="2">
                              <content styleCode="italics">Intervention </content>
                           </td>
                           <td> Anydoseadjustmentshould beguidedbyclinicaleffect (tolerabilityand efficacy). </td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20241219"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list>
                           <item>
                              <content styleCode="italics">Drugs Highly Bound to Plasma Protein:</content> Monitor for adverse reactions andreduce dosage of paroxetine or other protein-bound drugs (e.g., warfarin) aswarranted.(<linkHtml href="#_98fb8324-731b-1e24-7f26-087b47024334">7</linkHtml>)</item>
                           <item>
                              <content styleCode="italics">Drugs Metabolized by CYP2D6:</content> Reduce dosage of drugs metabolized byCYP2D6aswarranted.(<linkHtml href="#_98fb8324-731b-1e24-7f26-087b47024334">7</linkHtml>)</item>
                           <item>
                              <content styleCode="italics">Concomitantusewithtamoxifen:</content>Consideruseofanalternativeantidepressantwithlittleor noCYP2D6inhibition.(<linkHtml href="#_128b39fe-9a39-3ec7-99a3-672ce8d35f3d">5.11</linkHtml>,<linkHtml href="#_98fb8324-731b-1e24-7f26-087b47024334">7</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="_07477471-b669-f205-c7ce-057311cad48c">
               <id root="07aecfdc-2635-66ee-5a41-77068ace2f70"/>
               <code code="43684-0" displayName="USE IN SPECIFIC POPULATIONS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20210530"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list>
                           <item>
                              <content styleCode="italics">Pregnancy: </content>SSRI use, particularly later in pregnancy, may increase the risk for persistent pulmonary hypertension and symptoms of poor adaptation (respiratory distress, temperature instability, feeding difficulty, hypotonia, irritability) in the neonate. (<linkHtml href="#_f8c81c80-1de4-0c58-25c6-63646e66b4a3">8.1</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="_f8c81c80-1de4-0c58-25c6-63646e66b4a3">
                     <id root="0fc3a588-bd0b-1f6b-232c-e5082f1d3500"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Pregnancy Exposure Registry</content>
                        </paragraph>
                        <paragraph>There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antidepressants, including paroxetine, during pregnancy. Healthcare providers are encouraged to advise patients to register by calling the National Pregnancy Registry for Antidepressants 1-866-961-2388 or visiting online at https://womensmentalhealth.org/clinical-and-researchprograms/pregnancyregistry/antidepressants/.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>Based on data from published observational studies, exposure to SSRIs, particularly in the month before delivery, has been associated with a less than 2-fold increase in the risk of postpartum hemorrhage <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#_653d03c0-3732-f4ff-cd4d-3f78936c5075">5.5</linkHtml>) and Clinical Considerations].</content>
                        </paragraph>
                        <paragraph>Paroxetine is associated with a less than 2-fold increase in cardiovascular malformations when administered to a pregnant woman during the first trimester. While individual epidemiological studies on the association between paroxetine use and cardiac malformations have reported inconsistent findings, some meta-analyses of epidemiological studies have identified an increased risk of cardiovascular malformations (see Data). There are risks of persistent pulmonary hypertension of the newborn (PPHN) (see Data) and/or poor neonatal adaptation with exposure to selective serotonin reuptake inhibitors (SSRIs), including paroxetine during pregnancy. There also are risks associated with untreated depression in pregnancy (see Clinical Considerations). For women who intend to become pregnant or who are in their first trimester of pregnancy, paroxetine should be initiated only after consideration of the other available treatment options.</paragraph>
                        <paragraph>No evidence of treatment related malformations was observed in animal reproduction studies, when paroxetine was administered during the period of organogenesis at doses up to 50 mg/kg/day in rats and 6 mg/kg/day in rabbits. These doses are approximately 8 (rat) and less than 2 (rabbit) times the maximum recommended human dose (MRHD  60 mg) on an mg/m<sup>2</sup> basis. When paroxetine was administered to female rats during the last trimester of gestation and continued through lactation, there was an increase in the number of pup deaths during the first four days of lactation. This effect occurred at a dose of 1 mg/kg/day which is less than the MRHD on an mg/m<sup>2</sup> basis (See Data).</paragraph>
                        <paragraph>The background risks of major birth defects and miscarriage for the indicated populations are unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the US general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Clinical Considerations</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Disease-associated maternal and/or embryofetal risk</content>
                        </paragraph>
                        <paragraph>Women who discontinue antidepressants during pregnancy are more likely to experience a relapse of major depression than women who continue antidepressants. This finding is from a prospective, longitudinal study of 201 pregnant women with a history of major depressive disorder who were euthymic and taking antidepressants at the beginning of pregnancy. Consider the risk of untreated depression when discontinuing or changing treatment with antidepressant medication during pregnancy and the postpartum.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Maternal Adverse Reactions</content>
                        </paragraph>
                        <paragraph>Use of paroxetine tablets in the month before delivery may be associated with an increased risk of postpartum hemorrhage <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#_653d03c0-3732-f4ff-cd4d-3f78936c5075">5.5</linkHtml>)].</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Fetal/Neonatal adverse reactions</content>
                        </paragraph>
                        <paragraph>Neonates exposed to paroxetine and other SSRIs late in the third trimester have developed complications requiring prolonged hospitalization, respiratory support, and tube feeding. Such complications can arise immediately upon delivery. Reported clinical findings have included respiratory distress, cyanosis, apnea, seizures, temperature instability, feeding difficulty, vomiting, hypoglycemia, hypotonia, hypertonia, hyperreflexia, tremors, jitteriness, irritability, and constant crying. These findings are consistent with either a direct toxic effect of SSRIs or possibly a drug discontinuation syndrome. It should be noted that, in some cases, the clinical picture is consistent with serotonin syndrome <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#_cc482d0a-c6f1-da5a-37db-cf01b70fbb16">5.2</linkHtml>)].</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Data</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Human Data</content>
                        </paragraph>
                        <paragraph>Published epidemiological studies on the association between first trimester paroxetine use and cardiovascular malformations have reported inconsistent results; however, meta-analyses of population-based cohort studies published between 1996 to 2017 indicate a less than 2-fold increased risk for overall cardiovascular malformations. Specific cardiac malformations identified in two meta-analyses include an approximately 2 to 2.5-fold increased risk for right ventricular outflow tract defects. One meta-analysis also identified an increased risk (less than 2-fold) for bulbus cordis anomalies and anomalies of cardiac septal closure, and an increased risk for atrial septal defect (pooled OR 2.38, 95% CI 1.14 to 4.97). Important limitations of the studies included in these meta-analyses include potential confounding by indication, depression severity, and potential exposure misclassification.</paragraph>
                        <paragraph>Exposure to SSRIs, particularly later in pregnancy, may have an increased risk for PPHN. PPHN occurs in 1 to 2 per 1,000 live births in the general population and is associated with substantial neonatal morbidity and mortality.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Animal Data </content>
                        </paragraph>
                        <paragraph>Reproduction studies were performed at doses up to 50 mg/kg/day in rats and 6 mg/kg/day in rabbits administered during organogenesis. These doses are approximately 8 (rat) and less than 2 (rabbit) times the maximum recommended human dose (MRHD  60 mg) on an mg/m<sup>2 </sup>basis.</paragraph>
                        <paragraph>These studies have revealed no evidence of developmental effects. However, in rats, there was an increase in pup deaths during the first 4 days of lactation when dosing occurred during the last trimester of gestation and continued throughout lactation. This effect occurred at a dose of 1 mg/kg/day which is less than the MRHD on an mg/m<sup>2</sup> basis. The no effect dose for rat pup mortality was not determined. The cause of these deaths is not known.</paragraph>
                     </text>
                     <effectiveTime value="20250103"/>
                  </section>
               </component>
               <component>
                  <section ID="_4204ceb2-241a-5056-6745-fb0306331834">
                     <id root="c8ff2ac4-b732-61dd-a116-1fd92fb8fed3"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>Data from the published literature report the presence of paroxetine in human milk (see Data). There are reports of agitation, irritability, poor feeding and poor weight gain in infants exposed to paroxetine through breast milk (see Clinical Considerations). There are no data on the effect of paroxetine on milk production. The developmental and health benefits of breastfeeding should be considered along with the mothers clinical need for paroxetine and any potential adverse effects on the breastfed child from paroxetine or from underlying maternal condition.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Clinical Considerations</content>
                        </paragraph>
                        <paragraph>Infants exposed to paroxetine should be monitored for agitation, irritability, poor feeding and poor weight gain.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Data</content>
                        </paragraph>
                        <paragraph>Published literature suggests the presence of paroxetine in human milk with relative infant doses ranging between 0.4% to 2.2%, and a milk/plasma ratio of &lt;1. No significant amounts were detected in the plasma of infants after breastfeeding.</paragraph>
                     </text>
                     <effectiveTime value="20250103"/>
                  </section>
               </component>
               <component>
                  <section ID="_f8e8b646-c130-693a-ee85-6230eec4af0e">
                     <id root="b6ba0c81-29ef-624f-8fa7-c9913cf01731"/>
                     <code code="77291-3" codeSystem="2.16.840.1.113883.6.1" displayName="FEMALES &amp; MALES OF REPRODUCTIVE POTENTIAL SECTION"/>
                     <title>8.3 Females and Males of Reproductive Potential</title>
                     <text>
                        <paragraph>
                           <content styleCode="none"> Infertility</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Male</content>
                        </paragraph>
                        <paragraph>Based on findings from clinical studies, paroxetine may affect sperm quality which may impair fertility; it is not known if this effect is reversible<content styleCode="italics"> [see Nonclinical Toxicology (<linkHtml href="#_c3afd10b-ebfa-9e1e-bc96-97577a574f6c">13.1</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241220"/>
                  </section>
               </component>
               <component>
                  <section ID="_f399a731-bb7e-72b7-ef00-b849dffcc08e">
                     <id root="89031fe2-f321-df82-52ef-442d06584d68"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>The safety and effectiveness of paroxetine in pediatric patients have not been established <content styleCode="italics">[see BoxWarning]</content>.Effectivenesswasnotdemonstratedinthreeplacebo-controlledtrialsin752paroxetine-treatedpediatricpatientswithMDD.</paragraph>
                        <paragraph>Antidepressants increase the risk of suicidal thoughts and behaviors in pediatric patients <content styleCode="italics">[seeBoxedWarning,WarningsandPrecautions(<linkHtml href="#_9dff5b7a-4deb-c87c-5aa7-c4a74463c4e8">5.1</linkHtml>)].</content>DecreasedappetiteandweightlosshavebeenobservedinassociationwiththeuseofSSRIs.</paragraph>
                        <paragraph>In placebo-controlled clinical trials conducted with pediatric patients, the following adversereactions were reported in at least 2% of pediatric patients treated with paroxetine and occurred at arate at least twice that for pediatric patients receiving placebo: emotional lability (including self-harm, suicidal thoughts, attempted suicide, crying, and mood fluctuations), hostility, decreasedappetite,tremor, sweating, hyperkinesia, and agitation.</paragraph>
                        <paragraph>Adverse reactions upon discontinuation of treatment with paroxetine in the pediatric clinical trialsthat included a taper phase regimen, which occurred in at least 2% of patients and at a rate atleast twice that of placebo, were: emotional lability (including suicidal ideation, suicide attempt,moodchanges, and tearfulness), nervousness,dizziness, nausea,and abdominal pain.</paragraph>
                     </text>
                     <effectiveTime value="20230912"/>
                  </section>
               </component>
               <component>
                  <section ID="_b3cc2bac-7000-420c-92ef-88bdefadade5">
                     <id root="6d4f0824-cb0b-e3cb-5fa6-a25db7766ffd"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>In premarketing clinical trials with paroxetine, 17% of patients treated with paroxetine (approximately700) were 65 years of age or older. Pharmacokinetic studies revealed a decreased clearance inthe elderly, and a lower starting dose is recommended;, however, no overall differences in safetyor effectiveness were observed between elderly and younger patients <content styleCode="italics">[see Dosage andAdministration(<linkHtml href="#_e67c140b-fa03-cad9-26f1-ff27becbe06b">2.4</linkHtml>)</content>, <content styleCode="italics">Clinical Pharmacology (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_5511a139-d401-10fa-8008-50c47873c7b7">12.3</linkHtml>)].</content></paragraph>
                        <paragraph>SSRIs including paroxetine, have been associated with cases of clinically significant hyponatremiain elderly patients, who may be at greater risk for this adverse reaction <content styleCode="italics">[see Warnings andPrecautions(<linkHtml href="#_374de3a0-febe-dffe-139a-413f4ec088ca">5.7</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20210531"/>
                  </section>
               </component>
               <component>
                  <section ID="_b59c2d58-b330-ec75-371a-b1244e53fc73">
                     <id root="8eb9a428-4130-9838-ee3c-8d9108939de4"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>8.6 Renal and Hepatic Impairment</title>
                     <text>
                        <paragraph>Increased plasma concentrations of paroxetine occur in patients with renal and hepaticimpairment. The initial dosage of paroxetine should be reduced in patients with severe renalimpairmentandinpatientswithseverehepaticimpairment<content styleCode="italics">[seeDosageandAdministration(<linkHtml href="#_5511a139-d401-10fa-8008-50c47873c7b7">2.4</linkHtml>),ClinicalPharmacology (<linkHtml href="#_e67c140b-fa03-cad9-26f1-ff27becbe06b">12.3</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20210531"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="_01097895-55af-057d-1c5e-add7ecc918d5">
               <id root="1e5ddbcc-38db-e5d6-e857-a0444c573451"/>
               <code code="34088-5" displayName="OVERDOSAGE SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>The following have been reported with paroxetine tablet overdosage: </paragraph>
                  <list>
                     <item>Seizures, which may be delayed, and altered mental status including coma. </item>
                     <item>Cardiovascular toxicity, which may be delayed, including QRS and QTc interval prolongation. Hypertension most commonly seen, but rarely can see hypotension alone or with co-ingestants including alcohol. </item>
                     <item>Serotonin syndrome (patients with a multiple drug overdosage with other proserotonergic drugs may have a higher risk). </item>
                  </list>
                  <paragraph>Gastrointestinal decontamination with activated charcoal should be considered in patients who present early after a paroxetine overdose.</paragraph>
                  <paragraph>Consider contacting a poison center (1-800-222-1222) or a medical toxicologist for additional overdosage management recommendations.<br/>
                  </paragraph>
               </text>
               <effectiveTime value="20241219"/>
            </section>
         </component>
         <component>
            <section ID="_a3dc1870-7395-afc3-723a-897f3404bd6e">
               <id root="a70ba77c-fae1-3cbb-bc2f-7667f7f7aece"/>
               <code code="34089-3" displayName="DESCRIPTION SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Paroxetine tablets, USP contains paroxetine hydrochloride USP, an SSRI. It is the hydrochloride salt of aphenylpiperidine compound identified chemically as (-)-<content styleCode="italics">trans</content>-4<content styleCode="italics">R</content>-(4'-fluorophenyl)-3<content styleCode="italics">S</content>-[(3',4'-methylenedioxyphenoxy) methyl] piperidine hydrochloride anhydrous and has the empiricalformula of C<sub>19</sub>H<sub>20</sub>FNO<sub>3</sub>HCl. The molecular weight is 365.8 (329.4 as free base). Thestructuralformula of paroxetinehydrochlorideis:</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM690184452102"/>
                  </paragraph>
                  <paragraph>Paroxetinehydrochloride USPisanodorless,off-whitepowder,havingameltingpoint rangeof116Cto 120C and a solubilityof 5.4 mg/mL in water.</paragraph>
                  <paragraph>Each film-coated tablet, for oral administration, contains paroxetine hydrochloride equivalent to paroxetine as follows: 10 mg; 20 mg; 30 mg; 40 mg. Inactive ingredients consist of anhydrous lactose, hydroxypropyl cellulose, hypromellose, magnesium stearate, polyethylene glycol, sodium starch glycolate and titanium dioxide. Paroxetine tablets comply with USP Related Impurities Test 1.</paragraph>
               </text>
               <effectiveTime value="20230925"/>
            </section>
         </component>
         <component>
            <section ID="_c11961ef-63b0-645a-a566-cbe101a6dda3">
               <id root="59b77d14-2bd3-c1c9-1648-cbfe004dd0d0"/>
               <code code="34090-1" displayName="CLINICAL PHARMACOLOGY SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20210530"/>
               <component>
                  <section ID="_5a35936c-eb8d-d316-2774-5b1cb1533f37">
                     <id root="e02942af-7636-baf7-614f-6f56b58bd185"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title> 12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>ThemechanismofactionofparoxetineinthetreatmentofMDD,SAD,OCD,PD,GAD,andPTSDis unknown, but is presumed to be linked to potentiation of serotonergic activity in the centralnervoussystemresultingfrominhibitionofneuronalreuptakeofserotonin(5-hydroxy-tryptamine,5-HT).</paragraph>
                     </text>
                     <effectiveTime value="20210531"/>
                  </section>
               </component>
               <component>
                  <section ID="_5ad9dbbe-e4c5-dfad-c20c-3466cdd66181">
                     <id root="33e868ef-c507-383b-b244-25bed309c2a7"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>Studies at clinically relevant doses in humans have demonstrated that paroxetine blocks theuptakeofserotoninintohumanplatelets.Invitrostudiesinanimalsalsosuggestthatparoxetineis a potent and highly selective inhibitor of neuronal serotonin reuptake (SSRI) and has onlyvery weakeffectsonnorepinephrineanddopamineneuronalreuptake.</paragraph>
                     </text>
                     <effectiveTime value="20210531"/>
                  </section>
               </component>
               <component>
                  <section ID="_5511a139-d401-10fa-8008-50c47873c7b7">
                     <id root="e893d2e9-7be5-b414-fb1f-daa6e032ef9c"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>Nonlinearityinpharmacokineticsisobservedwithincreasingdosesofparoxetine.</paragraph>
                        <paragraph>In a meta-analysis of paroxetine from 4 studies done in healthy volunteers following multipledosing of 20 mg/day to 40 mg/day, males did not exhibit a significantly lower C<sub>max</sub> or AUC thanfemales.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Absorption</content>
                        </paragraph>
                        <paragraph>Paroxetinehydrochlorideiscompletelyabsorbedafteroraldosingofasolutionofthehydrochloridesalt.Inastudyinwhichnormalmalesubjects(n= 15)received30 mgtabletsdailyfor 30 days, steady-state paroxetine concentrations were achieved by approximately 10 days formost subjects, although it may take substantially longer in an occasional patient. At steady state,meanvaluesofC<sub>max</sub>, T<sub>max</sub>,C<sub>min</sub>,andT<sub></sub>were61.7ng/mL(CV45%),5.2hr.(CV10%), 30.7 ng/mL (CV 67%), and 21 hours (CV 32%), respectively. The steady-state C<sub>max</sub>and C<sub>min</sub>values were about 6 and 14 times what would be predicted from single-dose studies. Steady-statedrug exposure based on AUC<sub>0-24</sub> was about 8 times greater than would have been predicted fromsingle-dose data in these subjects. The excess accumulation is a consequence of the fact that 1 oftheenzymes that metabolizesparoxetine is readilysaturable.</paragraph>
                        <paragraph> Paroxetineisequallybioavailablefromthe oral suspension andtablet.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Effect of Food</content>
                        </paragraph>
                        <paragraph>The effects of food on the bioavailability of paroxetine were studied in subjects administered asingle dose with and without food. AUC was only slightly increased (6%) when drug wasadministered with food but the C<sub>max</sub>was 29% greater, while the time to reach peak plasmaconcentrationdecreasedfrom6.4 hours post-dosingto 4.9 hours.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Distribution</content>
                        </paragraph>
                        <paragraph>Paroxetinedistributesthroughoutthebody,includingtheCNS,withonly1%remainingintheplasma.</paragraph>
                        <paragraph>Approximately95%and93%ofparoxetineisboundtoplasmaproteinat100 ng/mLand400 ng/mL, respectively. Under clinical conditions, paroxetine concentrations would normally belessthan400 ng/mL.Paroxetinedoesnotaltertheinvitroproteinbindingofphenytoinorwarfarin.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Elimination</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Metabolism</content>
                        </paragraph>
                        <paragraph>Themeaneliminationhalf-lifeisapproximately21 hours(CV32%)afteroraldosingof30mgtabletsdaily for 30 days of paroxetine.In steady-state dose proportionality studies involving elderly and nonelderly patients, at doses of20 mg to 40 mg daily for the elderly and 20 mg to 50 mg daily for the nonelderly, somenonlinearity was observed in both populations, again reflecting a saturable metabolic pathway. Incomparison to C<sub>min</sub>values after 20 mg daily, values after 40 mg daily were only about 2 to 3timesgreater than doubled.</paragraph>
                        <paragraph>Paroxetine is extensively metabolized after oral administration. The principal metabolites arepolarandconjugated productsofoxidationand methylation,which arereadilycleared. Conjugates with glucuronic acid and sulfate predominate, and major metabolites have beenisolated and identified. Data indicate that the metabolites have no more than 1/50 the potency ofthe parent compound at inhibiting serotonin uptake. The metabolism of paroxetine isaccomplished in part by CYP2D6. Saturation of this enzyme at clinical doses appears to accountfor the nonlinearity of paroxetine kinetics with increasing dose and increasing duration oftreatment. The role of this enzyme in paroxetine metabolism also suggests potential drug-druginteractions <content styleCode="italics">[see Drug Interactions (<linkHtml href="#_98fb8324-731b-1e24-7f26-087b47024334">7</linkHtml>)].</content> Pharmacokinetic behavior of paroxetine has not beenevaluatedinsubjects whoare deficientin CYP2D6(poormetabolizers).</paragraph>
                        <paragraph>
                           <content styleCode="italics">Excretion</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics"/>Approximately 64% of a 30-mg oral solution dose of paroxetine was excreted in the urine with2% as the parent compound and 62% as metabolites over a 10-day post-dosing period. About36% was excreted in the feces (probably via the bile), mostly as metabolites and less than 1% astheparent compound overthe10-daypost-dosingperiod.</paragraph>
                        <paragraph>
                           <content styleCode="underline">DrugInteractionStudies</content>
                        </paragraph>
                        <paragraph>Thereareclinicallysignificant,knowndruginteractionsbetweenparoxetineandotherdrugs<content styleCode="italics">[seeDrugInteractions(<linkHtml href="#_98fb8324-731b-1e24-7f26-087b47024334">7</linkHtml>)].</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Figure1.ImpactofParoxetineonthePharmacokineticsofCo-AdministeredDrugs(log scale)</content>
                        </paragraph>
                        <paragraph>
                           <renderMultiMedia referencedObject="MM796253500334"/>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Figure2.ImpactofCo-AdministeredDrugsonthePharmacokineticsofParoxetine</content>
                        </paragraph>
                        <paragraph>
                           <renderMultiMedia referencedObject="MM420945102352"/>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Theophylline: </content>Reportsofelevatedtheophyllinelevelsassociatedwithparoxetinetreatmenthavebeen reported. While this interaction has not been formally studied, it is recommended thattheophyllinelevelsbemonitoredwhenthesedrugsareconcurrentlyadministered.</paragraph>
                        <paragraph>
                           <content styleCode="italics">DrugsMetabolizedbyCytochromeCYP3A4</content>
                        </paragraph>
                        <paragraph>An <content styleCode="italics">in vivo</content> interaction study involving the coadministration under steady-state conditions ofparoxetine and terfenadine, a substrate for CYP3A4, revealed no effect of paroxetine onterfenadine pharmacokinetics. In addition, <content styleCode="italics">in vitro</content> studies have shown ketoconazole, a potentinhibitor of CYP3A4 activity, to be at least 100 times more potent than paroxetine as aninhibitorof the metabolism of several substrates for this enzyme, including terfenadine, triazolam, and cyclosporine. Paroxetines extent of inhibition of CYP3A4 activity is not expected to be of clinical significance.</paragraph>
                        <paragraph>
                           <content styleCode="underline">SpecificPopulations</content>
                        </paragraph>
                        <paragraph>TheimpactofspecificpopulationsonthepharmacokineticsofparoxetineareshowninFigure3.</paragraph>
                        <paragraph>The recommended starting dosage and maximum dosage of paroxetineis reduced in elderlypatients,patientswithsevererenalimpairment,andpatientswithseverehepaticimpairment<content styleCode="italics">[seeDosage and Administration (<linkHtml href="#_4bfa2214-2145-6513-ebb8-8373f6763bb4">2.4</linkHtml>)</content>
                           <content styleCode="italics">]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Figure3.ImpactofSpecificPopulationonthePharmacokineticsofParoxetine(logscale)</content>
                        </paragraph>
                        <paragraph>
                           <renderMultiMedia referencedObject="MM805103925762"/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241220"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="_6d214bfb-5a99-4f91-4bb6-7c3e5f244ced">
               <id root="676475cc-a8ab-ca81-d085-cb814263436b"/>
               <code code="43680-8" displayName="NONCLINICAL TOXICOLOGY SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <text/>
               <effectiveTime value="20210530"/>
               <component>
                  <section ID="_c3afd10b-ebfa-9e1e-bc96-97577a574f6c">
                     <id root="453191a2-2dc2-1ad6-21ef-b149af7fd845"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title> 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Carcinogenesis</content>
                        </paragraph>
                        <paragraph>Two-year carcinogenicity studies were conducted in rodents given paroxetine in the diet at 1, 5, and 25 mg/kg/day (mice) and 1, 5, and 20 mg/kg/day (rats). These doses are up to 2 (mouse) and 3 (rat) times the MRHD of 60 mg on a mg/m<sup>2</sup> basis. There was a significantly greater number of male rats in the high-dose group with reticulum cell sarcomas (1/100, 0/50, 0/50, and 4/50 for control, low-, middle-, and high-dose groups, respectively) and a significantly increased linear trend across dose groups for the occurrence of lymphoreticular tumors in male rats. Female rats were not affected. Although there was a dose-related increase in the number of tumors in mice, there was no drug-related increase in the number of mice with tumors. The relevance of these findings to humans is unknown.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Mutagenesis</content>
                        </paragraph>
                        <paragraph>Paroxetine produced no genotoxic effects in a battery of 5 in vitro and 2 <content styleCode="italics">in vivo</content> assays that included the following: Bacterial mutation assay, mouse lymphoma mutation assay, unscheduled DNA synthesis assay, and tests for cytogenetic aberrations <content styleCode="italics">in vivo</content> in mouse bone marrow and in vitro in human lymphocytes and in a dominant lethal test in rats.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Impairment of Fertility</content>
                        </paragraph>
                        <paragraph>A reduced pregnancy rate was found in reproduction studies in rats at a dose of paroxetine of 15 mg/kg/day, which is 2 times the MRHD of 60 mg on a mg/m<sup>2</sup> basis. Irreversible lesions occurred in the reproductive tract of male rats after dosing in toxicity studies for 2 to 52 weeks. These lesions consisted of vacuolation of epididymal tubular epithelium at 50 mg/kg/day and atrophic changes in the seminiferous tubules of the testes with arrested spermatogenesis at 25 mg/kg/day (8 and 4 times the MRHD of 60 mg on a mg/m<sup>2</sup> basis).</paragraph>
                     </text>
                     <effectiveTime value="20241219"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="_c293be19-18fd-a03c-4f19-f1bd1704c6a3">
               <id root="7bdcc71b-8722-618b-3efa-8b9b917b5b8e"/>
               <code code="34092-7" displayName="CLINICAL STUDIES SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>14 CLINICAL STUDIES</title>
               <effectiveTime value="20210530"/>
               <component>
                  <section ID="_cf055595-2d38-33b4-3003-5517b4fdb380">
                     <id root="a878b47e-c2de-d9f9-56c3-86609ef3b999"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>14.1 Major Depressive Disorder</title>
                     <text>
                        <paragraph>The efficacy of paroxetine as a treatment for major depressive disorder (MDD) has been establishedin 6 placebo-controlled studies of patients with MDD (aged 18 to 73). In these studies, paroxetinewas shown to be statistically significantly more effective than placebo in treating MDD by atleast 2 of the following measures: Hamilton Depression Rating Scale (HDRS), the Hamiltondepressed mood item, and the Clinical Global Impression (CGI)-Severity of Illness. Paroxetine wasstatistically significantly better than placebo in improvement of the HDRS sub-factor scores,includingthe depressedmood item,sleep disturbancefactor, andanxietyfactor.</paragraph>
                        <paragraph>Long-term efficacy of paroxetine for treatment of MDD in outpatients was demonstrated in arandomizedwithdrawalstudy.Patientswhorespondedtoparoxetine(HDRStotalscore&lt;8)duringan initial 8-week open-labeltreatment phase were then randomized to continue paroxetine orplacebo, for up to 1 year. Patients treated with paroxetine demonstrated a statistically significantlowerrelapserateduringthewithdrawalphase(15%)comparedtothoseonplacebo(39%). Effectivenesswassimilarformaleandfemalepatients.</paragraph>
                     </text>
                     <effectiveTime value="20241220"/>
                  </section>
               </component>
               <component>
                  <section ID="_0a2620ef-25d9-73d4-05c6-12a83ec3dd02">
                     <id root="2e885b5a-72ff-c5cf-b28c-71e481971fbf"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>14.2 Obsessive Compulsive Disorder</title>
                     <text>
                        <paragraph>The effectiveness of paroxetine in the treatment of obsessive compulsive disorder (OCD) wasdemonstrated in two 12-week multicenter placebo-controlled studies of adult outpatients (Studies1 and 2). Patients had moderate to severe OCD (DSM-IIIR) with mean baseline ratings on theYaleBrownObsessiveCompulsiveScale(YBOCS)totalscorerangingfrom23to26.Instudy1,adose-range findingstudy,patients receivedfixed dailydosesof paroxetine20 mg,40mg, or 60 mg. Study 1demonstrated that daily doses of paroxetine 40 mg and 60 mg are effective in thetreatment of OCD. Patients receiving doses of paroxetine 40 mg and 60 mg experienced a meanreduction of approximately 6 and 7 points, respectively, on the YBOCS total score which wasstatistically significantly greater than the approximate 4-point reduction at 20 mg and a 3-pointreductionintheplacebo-treatedpatients.Study2wasaflexible-dosestudycomparingparoxetine20mg to 60 mg daily with clomipramine 25 mg to 250 mg daily or placebo). In this study, patientsreceiving paroxetine experienced a mean reduction of approximately 7 points on the YBOCS totalscore,whichwasstatisticallysignificantlygreaterthanthemeanreductionofapproximately 4points inplacebo-treated patients.</paragraph>
                        <paragraph>The following table provides the outcome classification by treatment group on GlobalImprovementitemsof theClinicalGlobal Impression(CGI)scale forStudy1.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 10: Outcome Classification (%) on CGI-Global Improvement Item for Completers inStudy1 in Patients with OCD</content>
                        </paragraph>
                        <table frame="border" rules="all">
                           <tbody>
                              <tr>
                                 <td colspan="5"></td>
                              </tr>
                              <tr>
                                 <td rowspan="2">
                                    <content styleCode="bold">Outcome</content>
                                    <br/>
                                    <content styleCode="bold">Classification</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">Placebo</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">Paroxetine Tablets <br/>20 mg</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">Paroxetine Tablets <br/>40 mg</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">Paroxetine Tablets<br/> 60 mg</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td>
                                    <content styleCode="bold">(n=74)</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">(n=75)</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">(n=66)</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">(n=66)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td></td>
                                 <td align="center">
                                    <content styleCode="bold">%</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">%</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">%</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">%</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td>Worse</td>
                                 <td>14</td>
                                 <td>7</td>
                                 <td>7</td>
                                 <td>3</td>
                              </tr>
                              <tr>
                                 <td>NoChange</td>
                                 <td>44</td>
                                 <td>35</td>
                                 <td>22</td>
                                 <td>19</td>
                              </tr>
                              <tr>
                                 <td>MinimallyImproved</td>
                                 <td>24</td>
                                 <td>33</td>
                                 <td>29</td>
                                 <td>34</td>
                              </tr>
                              <tr>
                                 <td>MuchImproved</td>
                                 <td>11</td>
                                 <td>18</td>
                                 <td>22</td>
                                 <td>24</td>
                              </tr>
                              <tr>
                                 <td>VeryMuchImproved</td>
                                 <td>7</td>
                                 <td>7</td>
                                 <td>20</td>
                                 <td>20</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Subgroup analyses did not indicate that there were any differences in treatment outcomes as afunctionofage orgender.</paragraph>
                        <paragraph>The long-term efficacyof paroxetine for the treatment ofOCD was established in a long-termextension to Study 1. Patients who responded to paroxetine during the 3-month double-blind phaseand a 6-month extension on open-label paroxetine 20 mg to 60 mg daily were randomized to either paroxetine or placebo in a 6-month double-blind relapse prevention phase. Patients randomized toparoxetinewerestatisticallysignificantly lesslikelyto relapsethanplacebo-treated patients.</paragraph>
                        <paragraph/>
                     </text>
                     <effectiveTime value="20250103"/>
                  </section>
               </component>
               <component>
                  <section ID="_6f2af2ac-bf99-1ae1-9a54-007bcd1d7158">
                     <id root="e05b9df7-7150-ecb5-20aa-befdcb9836c1"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>14.3 Panic Disorder</title>
                     <text>
                        <paragraph>The effectiveness of paroxetine in the treatment of panic disorder (PD) was demonstrated in three10 to 12-week multicenter, placebo-controlled studies of adult outpatients (Studies 1, 2, and 3).Patients had PD (DSM-IIIR), with or without agoraphobia. In these studies, paroxetine was shownto be statistically significantly more effective than placebo in treating PD by at least 2 out of 3measures of panic attack frequency and on the Clinical Global Impression Severity of Illnessscore.</paragraph>
                        <paragraph>Study1wasa10-weekdose-rangefindingstudy;patientsreceivedfixeddosesofparoxetine10mg,20 mg, or 40 mg daily or placebo. A statistically significant difference from placebo wasobserved only for the paroxetine 40 mg daily group. At endpoint, 76% of patients receiving paroxetine40mg dailywere freeof panicattacks, comparedto 44%of placebo-treated patients.</paragraph>
                        <paragraph>Study 2 was a 12-week flexible-dose study comparing paroxetine 10 mg to 60 mg daily andplacebo. At endpoint, 51% of paroxetine-treated patients were free of panic attacks compared to32%ofplacebo-treatedpatients.</paragraph>
                        <paragraph>Study 3 was a 12-week flexible-dose study comparing paroxetine 10 mg to 60 mg daily to placeboin patients concurrently receiving standardized cognitive behavioral therapy. At endpoint, 33%of the paroxetine-treated patients showed a reduction to 0 or 1 panic attacks compared to 14% ofplacebo-treatedpatients. In Studies 2 and 3, the mean paroxetine dose for completers at endpoint was approximately 40 mgdaily.</paragraph>
                        <paragraph>Long-term efficacy of paroxetine in PD was demonstrated in an extension to Study 1. Patients whoresponded to paroxetine during the 10-week double-blind phase and during a 3-month double-blindextension phase were randomized to either paroxetine 10 mg, 20 mg, or 40 mg daily or placebo in a3-month double-blind relapse prevention phase. Patients randomized to paroxetine were statisticallysignificantlyless likely to relapse than placebo-treatedpatients.</paragraph>
                        <paragraph>Subgroup analyses did not indicate that there were any differences in treatment outcomes as afunctionofage orgender.</paragraph>
                     </text>
                     <effectiveTime value="20250103"/>
                  </section>
               </component>
               <component>
                  <section ID="_8d6d1e2b-52b8-a318-0043-ff345d71c6f0">
                     <id root="7ef8acec-0cf3-17a7-5f2c-cdff7a18741a"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>14.4 Social Anxiety Disorder</title>
                     <text>
                        <paragraph>The effectiveness of paroxetine in the treatment of social anxiety disorder (SAD) was demonstratedin three 12-week, multicenter, placebo-controlled studies (Studies 1, 2, and 3) of adultoutpatients with SAD (DSM-IV). In these studies, the effectiveness of paroxetine compared toplacebo was evaluated on the basis of (1) the proportion of responders, as defined by a ClinicalGlobal Impression (CGI) Improvement score of 1 (very much improved) or 2 (much improved),and(2) change frombaseline in theLiebowitz Social AnxietyScale (LSAS).</paragraph>
                        <paragraph>Studies 1 and 2 were flexible-dose studies comparing paroxetine 20 mg to 50 mg daily and placebo.ParoxetinedemonstratedstatisticallysignificantsuperiorityoverplaceboonboththeCGIImprovement responder criterion and the Liebowitz Social Anxiety Scale (LSAS). In Study 1, forpatientswhocompletedtoweek 12,69%ofparoxetine-treatedpatientscomparedto29%ofplacebo-treatedpatientswereCGIImprovementresponders.InStudy2,CGIImprovementresponderswere77%and42%fortheparoxetine-andplacebo-treatedpatients,respectively.</paragraph>
                        <paragraph>Study3wasa12-weekstudycomparingfixeddosesofparoxetine20mg,40mg,or60mgdailywithplacebo. Paroxetine 20 mg was statistically significantly superior to placebo on both the LSAS TotalScoreandtheCGIImprovementrespondercriterion;thereweretrendsforsuperiorityoverplacebofor the paroxetine 40 mg and 60 mg daily dose groups. There was no indication in this study of anyadditionalbenefitfordoseshigherthan 20mgdaily.</paragraph>
                        <paragraph>Subgroup analyses generally did not indicate differences in treatment outcomes as a function ofage, race, or gender.</paragraph>
                     </text>
                     <effectiveTime value="20250103"/>
                  </section>
               </component>
               <component>
                  <section ID="_f95f997f-af31-552a-98d8-3ce397ab16c2">
                     <id root="812fbe3d-f366-9024-b958-74de6f793f69"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>14.5 Generalized Anxiety Disorder</title>
                     <text>
                        <paragraph>The effectiveness of paroxetine in the treatment of generalized anxiety disorder (GAD) wasdemonstrated in two 8-week, multicenter, placebo-controlled studies (Studies 1 and 2) of adultoutpatientswithGAD(DSM-IV).</paragraph>
                        <paragraph>Study 1 was an 8-week study comparing fixed doses ofparoxetine 20 mg or 40 mg daily withplacebo. Doses of paroxetine 20 mg or 40 mgwere both demonstrated to be statisticallysignificantlysuperiortoplaceboontheHamiltonRatingScaleforAnxiety(HAM-A)totalscore.</paragraph>
                        <paragraph>Therewasnotsufficientevidenceinthisstudytosuggestagreaterbenefitfortheparoxetine40mgdailydose compared to the 20 mg daily dose.</paragraph>
                        <paragraph>Study2wasaflexible-dosestudycomparingparoxetine20mgto50mgdailyandplacebo.Paroxetine demonstrated statistically significant superiority over placebo on the Hamilton Rating Scale forAnxiety(HAM-A) total score.</paragraph>
                        <paragraph>A third study, a flexible-dose study comparing paroxetine 20 mg to 50 mg daily to placebo, did notdemonstrate statistically significant superiority of paroxetine over placebo on the Hamilton RatingScalefor Anxiety (HAM-A) total score, the primary outcome.</paragraph>
                        <paragraph>Subgroup analyses did not indicate differences in treatment outcomes as a function of race orgender.Therewereinsufficientelderlypatientstoconductsubgroupanalysesonthebasisofage.</paragraph>
                        <paragraph>In a long-term trial, 566 patients meeting DSM-IV criteria for GAD, who had responded during asingle-blind, 8-week acute treatment phase with paroxetine 20 mg to 50 mg daily, were randomizedto continuation of paroxetine at their same dose, or to placebo, for up to 24 weeks of observation forrelapse. Response during the single-blind phase was defined by having a decrease of  2 pointscompared to baseline on the CGI-Severity of Illness scale, to a score of  3. Relapse during thedouble-blind phase was defined as an increase of  2 points compared to baseline on the CGI-Severity of Illness scale to a score of  4, or withdrawal due to lack of efficacy. Patientscontinuing to receive paroxetine experienced a statistically significantly lower relapse rate over thesubsequent24 weeks compared to those receiving placebo.</paragraph>
                     </text>
                     <effectiveTime value="20250103"/>
                  </section>
               </component>
               <component>
                  <section ID="_aeea5a9e-ddad-8f52-acdc-50cab77e3b4c">
                     <id root="0a5fa73f-e530-fcf5-faab-a88f4f2407a3"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>14.6 Posttraumatic Stress Disorder</title>
                     <text>
                        <paragraph>The effectiveness of paroxetine in the treatment of Posttraumatic Stress Disorder (PTSD) wasdemonstrated in two 12-week, multicenter, placebo-controlled studies (Studies 1 and 2) of adultoutpatients who met DSM-IV criteria for PTSD. The mean duration of PTSD symptoms for the 2studies combined was 13 years (ranging from 0.1 year to 57 years). The percentage of patientswith secondary MDD or non-PTSD anxiety disorders in the combined 2 studies was 41% (356outof858patients)and40%(345outof858patients),respectively.Studyoutcomewasassessed by (1) the Clinician-Administered PTSD Scale Part 2 (CAPS-2) score and (2) theClinical Global Impression-Global Improvement Scale (CGI-I). The CAPS-2 is a multi-iteminstrument that measures 3 aspects of PTSD with the following symptom clusters:Reexperiencing/intrusion, avoidance/numbing and hyperarousal. The 2 primary outcomes foreachtrialwere(1) changefrombaselineto endpointonthe CAPS-2totalscore(17 items),and (2) proportion of responders on the CGI-I, where responders were defined as patients having ascoreof 1 (very muchimproved)or2(muchimproved).</paragraph>
                        <paragraph>Study 1 was a 12-week study comparing fixed doses of paroxetine 20 mg or 40 mg daily to placebo.Doses of paroxetine 20 mg and 40 mg were demonstrated to be statistically significantly superior toplacebo on change from baseline for the CAPS-2 total score and on proportion of responders ontheCGI-I.There wasnotsufficientevidenceinthis studytosuggest agreaterbenefit forthe 40mg daily dosecompared to the 20mg daily dose. Study 2 was a 12-week flexible-dose study comparing paroxetine 20 mg to 50 mg daily to placebo.Paroxetine was demonstrated to be significantly superior to placebo on change from baseline for theCAPS-2total scoreand on proportion of responders on the CGI-I.</paragraph>
                        <paragraph>A third study, a flexible-dose study comparing paroxetine 20 mg to 50 mg daily to placebo,demonstrated paroxetine to be statistically significantly superior to placebo on change from baselineforCAPS-2totalscore,butnotonproportionofrespondersontheCGI-I.</paragraph>
                        <paragraph>The majority of patients in these trials were women (68% women: 377 out of 551 subjects inStudy 1 and 66% women: 202 out of 303 subjects in Study 2). Subgroup analyses did notindicate differences in treatment outcomes as a function of gender. There were an insufficientnumber of patients who were 65 years and older or were non-Caucasian to conduct subgroupanalyses onthe basis of age or race,respectively.</paragraph>
                     </text>
                     <effectiveTime value="20210206"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="_74D7E066-AB1D-48D6-D7BF-BF1C347657D3">
               <id root="db56a850-94cd-caa8-39a9-719603f6bc6c"/>
               <code code="34069-5" displayName="HOW SUPPLIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>Paroxetine tablets, USPareovalshaped film-coated tabletssuppliedas:</paragraph>
                  <table frame="box" rules="all">
                     <thead>
                        <tr>
                           <td>
                              <content styleCode="bold">Tablet<br/>Strength</content>
                           </td>
                           <td>
                              <content styleCode="bold">Color</content>
                           </td>
                           <td>
                              <content styleCode="bold">Engraved Descriptors</content>
                           </td>
                           <td>
                              <content styleCode="bold">Package<br/>Configuration</content>
                           </td>
                           <td>
                              <content styleCode="bold">NDCNumber</content>
                           </td>
                        </tr>
                     </thead>
                     <tbody>
                        <tr>
                           <td>10mg</td>
                           <td>White to off-white </td>
                           <td>Engraved APO &amp; partial bisect score on one side,097 on the other. </td>
                           <td>Bottlesof 30</td>
                           <td>NDC60505-0097-1</td>
                        </tr>
                        <tr>
                           <td>10mg</td>
                           <td>White to off-white</td>
                           <td>Engraved APO &amp; partial bisect score on one side,097 on the other</td>
                           <td>Bottlesof 100</td>
                           <td>NDC 60505-0097-2</td>
                        </tr>
                        <tr>
                           <td>10mg</td>
                           <td>White to off-white</td>
                           <td>Engraved APO &amp; partial bisect score on one side,097 on the other</td>
                           <td>Bottlesof 1,000</td>
                           <td>NDC 60505-0097-4</td>
                        </tr>
                        <tr>
                           <td>20mg</td>
                           <td>White to off-white</td>
                           <td>Engraved APO &amp; partial bisect score on one side,083 on the other</td>
                           <td>Bottlesof 30</td>
                           <td>NDC60505-0083-1</td>
                        </tr>
                        <tr>
                           <td>20mg</td>
                           <td>White to off-white</td>
                           <td>Engraved APO &amp; partial bisect score on one side,083 on the other</td>
                           <td>Bottlesof 100</td>
                           <td>NDC 60505-0083-2</td>
                        </tr>
                        <tr>
                           <td>20mg</td>
                           <td>White to off-white</td>
                           <td>Engraved APO &amp; partial bisect score on one side,083 on the other</td>
                           <td>Bottlesof 1,000</td>
                           <td>NDC 60505-0083-4</td>
                        </tr>
                        <tr>
                           <td>30mg</td>
                           <td>White to off-white</td>
                           <td>Engraved APO on one side &amp; 084 on the other side</td>
                           <td>Bottlesof 30</td>
                           <td>NDC60505-0084-1</td>
                        </tr>
                        <tr>
                           <td>30mg</td>
                           <td>White to off-white</td>
                           <td>Engraved APO on one side &amp; 084 on the other side</td>
                           <td>Bottlesof 100</td>
                           <td>NDC 60505-0084-2</td>
                        </tr>
                        <tr>
                           <td>30mg</td>
                           <td>White to off-white</td>
                           <td>Engraved APO on one side &amp; 084 on the other side</td>
                           <td>Bottlesof 1,000</td>
                           <td>NDC 60505-0084-4</td>
                        </tr>
                        <tr>
                           <td>40mg</td>
                           <td>White to off-white</td>
                           <td>Engraved APO on one side &amp; 101 on the other side</td>
                           <td>Bottlesof 30</td>
                           <td>NDC60505-0101-1</td>
                        </tr>
                        <tr>
                           <td>40mg</td>
                           <td>White to off-white</td>
                           <td>Engraved APO on one side &amp; 101 on the other side</td>
                           <td>Bottlesof 100</td>
                           <td>NDC 60505-0101-2</td>
                        </tr>
                        <tr>
                           <td>40mg</td>
                           <td>White to off-white</td>
                           <td>Engraved APO on one side &amp; 101 on the other side</td>
                           <td>Bottlesof 1,000</td>
                           <td>NDC 60505-0101-4</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>Storetabletsat20Cand25C(68Fand77F) excursions permitted from 15C to 30C (59F to 86F) [see USP Controlled Room Temperature].</paragraph>
                  <paragraph/>
               </text>
               <effectiveTime value="20250103"/>
            </section>
         </component>
         <component>
            <section ID="_98212be4-b3d2-f309-c45f-dfe8092fea38">
               <id root="73b14c70-b1e7-7a46-95f7-ad0bbb3742c9"/>
               <code code="34076-0" displayName="INFORMATION FOR PATIENTS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>AdvisethepatienttoreadtheFDA-approvedpatientlabeling(MedicationGuide).</paragraph>
                  <paragraph>
                     <content styleCode="underline"/>
                     <content styleCode="underline">SuicidalThoughtsandBehaviors</content>
                  </paragraph>
                  <paragraph>Advise patients and caregivers to look for the emergence of suicidality, especially early duringtreatment and when the dosage is adjusted up or down, and instruct them to report suchsymptomstothehealthcareprovider<content styleCode="italics">[seeBoxedWarningandWarningsandPrecautions(<linkHtml href="#_9dff5b7a-4deb-c87c-5aa7-c4a74463c4e8">5.1</linkHtml>)].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">SerotoninSyndrome</content>
                  </paragraph>
                  <paragraph>Cautionpatientsabouttheriskofserotoninsyndrome,particularlywiththeconcomitantuseofparoxetine with other serotonergic drugs including triptans, tricyclic antidepressants, opioids,lithium, tryptophan, buspirone, amphetamines, St. Johns Wort, and with drugs thatimpair metabolism of serotonin (in particular, MAOIs, both those intended to treat psychiatricdisordersandalsoothers,suchaslinezolid).Instructpatientstocontacttheirhealth careproviderorreporttotheemergencyroomifthey<br/>experiencesignsorsymptomsofserotoninsyndrome<content styleCode="italics">[see Warnings andPrecautions (<linkHtml href="#_cc482d0a-c6f1-da5a-37db-cf01b70fbb16">5.2</linkHtml>), DrugInteractions(<linkHtml href="#_98fb8324-731b-1e24-7f26-087b47024334">7</linkHtml>)].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">ConcomitantMedications</content>
                  </paragraph>
                  <paragraph>Advisepatientstoinformtheirphysicianiftheyaretaking,orplantotake,anyprescriptionorover-the-counter drugs, since there is a potential for drug-drug interactions <content styleCode="italics">[see Warning andPrecautions (<linkHtml href="#_d5cd4ce9-823a-e580-7c7e-dc5b09972393">5.3</linkHtml>),DrugInteractions(<linkHtml href="#_98fb8324-731b-1e24-7f26-087b47024334">7</linkHtml>)].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">IncreasedRiskofBleeding</content>
                  </paragraph>
                  <paragraph>Inform patients about the concomitant use of paroxetine with aspirin, NSAIDs, other antiplateletdrugs, warfarin, or other anticoagulants because the combined use has been associated with anincreasedriskofbleeding.Advisepatientstoinformtheirhealthcareprovidersiftheyaretakingor planning to take any prescription or over-the-counter medications that increase the risk ofbleeding<content styleCode="italics">[seeWarningsand Precautions(<linkHtml href="#_653d03c0-3732-f4ff-cd4d-3f78936c5075">5.5</linkHtml>)].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">ActivationofMania/Hypomania</content>
                  </paragraph>
                  <paragraph>Advise patients and their caregivers to observe for signs of activation of mania/hypomania andinstructthemtoreportsuchsymptomstothehealthcareprovider<content styleCode="italics">[seeWarningsandPrecautions(<linkHtml href="#_5763f641-3be2-01de-77ca-bd14b86b0748">5.6</linkHtml>)].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">DiscontinuationSyndrome</content>
                  </paragraph>
                  <paragraph>Advisepatientsnottoabruptlydiscontinueparoxetineandtodiscussanytaperingregimenwiththeir healthcare provider. Inform patients that adverse reactions can occur when paroxetine isdiscontinued<content styleCode="italics">[See Warnings and Precautions (<linkHtml href="#_374de3a0-febe-dffe-139a-413f4ec088ca">5.7</linkHtml>)].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Sexual Dysfunction</content>
                  </paragraph>
                  <paragraph>Advise patients that use of paroxetine may cause symptoms of sexual dysfunction in both male and female patients. Inform patients that they should discuss any changes in sexual function and potential management strategies with their healthcare provider <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#_5237cde6-a03a-a95b-df20-e23a49e6505e">5.13</linkHtml>)].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Allergic Reactions</content>
                  </paragraph>
                  <paragraph>Advise patients to notify their healthcare provider if they develop an allergic reaction such as rash, hives, swelling, or difficulty breathing <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#_5c7b35e4-0c3b-7de7-2c8b-c5e7f77ffcd4">6.1</linkHtml>, 6.2)].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Embryo-Fetal Toxicity</content>
                  </paragraph>
                  <paragraph>Advise women to notify their healthcare provider if they become pregnant or intend to become pregnant during treatment with paroxetine. Advise women of risks associated with first trimester use of paroxetine and that use later in pregnancy may lead to an increased risk for neonatal complications requiring prolonged hospitalization, respiratory support, tube feeding, and/or persistent pulmonary hypertension of the newborn (PPHN) <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#_25e0dbe0-a5e5-c7fc-94b2-5f1f881cec3d">5.4</linkHtml>)</content>, <content styleCode="italics">Use in Specific Populations (<linkHtml href="#_f8c81c80-1de4-0c58-25c6-63646e66b4a3">8.1</linkHtml>)].</content> Advise women that there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to paroxetine during pregnancy <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#_25e0dbe0-a5e5-c7fc-94b2-5f1f881cec3d">5.4</linkHtml>), Use in Specific Populations (</content>
                     <content styleCode="italics">
                        <linkHtml href="#_f8c81c80-1de4-0c58-25c6-63646e66b4a3">8.1</linkHtml>)].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Lactation</content>
                  </paragraph>
                  <paragraph>Advise breastfeeding women using paroxetine to monitor infants for agitation, irritability, poor feeding, and poor weight gain and to seek medical care if they notice these signs <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#_4204ceb2-241a-5056-6745-fb0306331834">8.2</linkHtml>)].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Females and Males of Reproductive Potential</content>
                  </paragraph>
                  <paragraph>Advise men that paroxetine may affect sperm quality, which may impair fertility; it is not known if this effect is reversible <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#_f8e8b646-c130-693a-ee85-6230eec4af0e">8.3</linkHtml>)].</content>
                  </paragraph>
                  <paragraph>Dispense with Medication Guide available at <content styleCode="underline">https://www.apotex.com/products/us/mg.asp </content>
                     <content styleCode="none">to each patient.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">APOTEX INC.</content>
                     <content styleCode="bold"/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">PAROXETINE TABLETS, USP</content>
                     <content styleCode="bold"/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">10 mg, 20 mg, 30 mg and 40</content><content styleCode="bold">mg</content>
                  </paragraph>
                  <table rules="none">
                     <tbody>
                        <tr>
                           <td>
                              <content styleCode="bold">Manufactured by:</content>
                           </td>
                           <td>
                              <content styleCode="bold">Manufactured for:</content>
                           </td>
                        </tr>
                        <tr>
                           <td>Apotex Inc. </td>
                           <td>Apotex Corp. </td>
                        </tr>
                        <tr>
                           <td>Toronto, Ontario </td>
                           <td>Weston, Florida </td>
                        </tr>
                        <tr>
                           <td>Canada M9L 1T9 </td>
                           <td>USA 33326 </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>Revision: 18</paragraph>
               </text>
               <effectiveTime value="20250103"/>
            </section>
         </component>
         <component>
            <section ID="_a22f8456-aebb-45e0-7d12-d3edce90e2b7">
               <id root="ea7abeb3-4aa6-a3e8-3283-9197d38b8bc9"/>
               <code code="42231-1" displayName="SPL MEDGUIDE SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>MEDICATION GUIDE</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Paroxetine <content styleCode="bold">(pa rox</content>'<content styleCode="bold">e teen)</content> Tablets, USP</content>
                     <content styleCode="bold"/>
                  </paragraph>
                  <paragraph> Medication Guide available at <content styleCode="underline">https://www.apotex.com/products/us/mg.asp</content> to each patient. </paragraph>
                  <paragraph>
                     <content styleCode="bold">What is the most important information I should know about paroxetine tablets? </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold"> Paroxetine tabletscancauseserioussideeffects,including:</content>
                  </paragraph>
                  <list>
                     <item>
                        <content styleCode="bold">Increased risk of suicidal thoughts or actions. </content>Paroxetine tablets and other antidepressant medicines may increase suicidalthoughts and actions in some people 24 years of age and younger, especially within the <content styleCode="bold">first few months of treatment orwhenthedoseischanged</content>.<content styleCode="bold">Paroxetine tablets arenotforuseinchildren.</content>
                        <list>
                           <item>
                              <content styleCode="bold">Depression or other mental illnesses are the most important causes of suicidal thoughts and actions.Howcan Iwatchforandtryto preventsuicidal thoughts andactions?</content>
                           </item>
                           <item>Pay close attention to any changes, especially sudden changes in mood, behavior, thoughts or feelings or if youdevelop suicidal thoughts or actions. This is very important when an antidepressant medicine is started or when thedose ischanged.</item>
                           <item>Call your healthcare provider right away to report new or sudden changes in mood, behavior, thoughts or feelings or ifyoudevelopsuicidalthoughts oractions.</item>
                           <item>Keep all follow-up visits with your healthcare provider as scheduled. Call your healthcare provider between visits asneeded,especiallyifyou haveconcernsaboutsymptoms.</item>
                        </list>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Call your healthcare provider or get emergency medical help right away if you have any of the followingsymptoms,especiallyif theyare new,worse, orworryyou:</content>
                  </paragraph>
                  <list>
                     <item>
                        <list>
                           <item>attemptstocommitsuicide</item>
                           <item>actingaggressiveorviolent</item>
                           <item>neworworsedepression</item>
                           <item>feelingagitated,restless,angry,orirritable</item>
                           <item>anincreaseinactivityandtalkingmorethanwhatis normal for you</item>
                           <item>actingon dangerousimpulses</item>
                           <item>thoughts about suicideordying</item>
                           <item>neworworseanxietyorpanicattacks</item>
                           <item>troublesleeping</item>
                           <item>other unusual changes in behavior or mood </item>
                        </list>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Whatareparoxetine tablets?</content>
                  </paragraph>
                  <paragraph>Paroxetine tabletsaretheprescriptionmedicineusedinadultstotreat:</paragraph>
                  <list>
                     <item>AcertaintypeofdepressioncalledMajorDepressiveDisorder(MDD)</item>
                     <item>ObsessiveCompulsiveDisorder(OCD)</item>
                     <item>PanicDisorder(PD)</item>
                     <item>SocialAnxietyDisorder(SAD)</item>
                     <item>GeneralizedAnxietyDisorder(GAD)</item>
                     <item>PosttraumaticStressDisorder(PTSD)</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Donottakeparoxetine tablets if you:</content>
                  </paragraph>
                  <list>
                     <item>takeamonoamineoxidaseinhibitor(MAOI)</item>
                     <item>havestoppedtakinganMAOIinthelast14days</item>
                     <item>arebeingtreatedwiththeantibioticlinezolidortheintravenousmethyleneblue</item>
                     <item>aretaking pimozide</item>
                     <item>aretakingthioridazine</item>
                     <item>areallergictoparoxetineoranyoftheingredientsinparoxetine tablets.SeetheendofthisMedicationGuideforacompletelistofingredientsinparoxetine tablets.</item>
                  </list>
                  <paragraph>Ask your healthcare provider or pharmacist if you are not sure if you take an MAOI or one of these medicines, including theantibioticlinezolidorintravenousmethyleneblue.</paragraph>
                  <paragraph>
                     <content styleCode="bold">DonotstarttakinganMAOIforatleast14daysafteryoustoptreatmentwithparoxetine tablets.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Beforetakingparoxetine tablets,tellyourhealthcareprovideraboutallyourmedicalconditions,includingifyou:</content>
                  </paragraph>
                  <list>
                     <item>haveheartproblems</item>
                     <item>haveorhadbleedingproblems</item>
                     <item>have,orhaveafamilyhistoryof,bipolardisorder,maniaorhypomania</item>
                     <item>haveorhadseizuresorconvulsions</item>
                     <item>haveglaucoma(highpressureintheeye)</item>
                     <item>havelowsodiumlevelsinyourblood</item>
                     <item>haveboneproblems</item>
                     <item>havekidneyorliverproblems</item>
                     <item>arepregnantorplantobecomepregnant.paroxetinemayharmyourunbornbaby.</item>
                     <item>
                        <list>
                           <item>Taking paroxetine during your first trimester of pregnancy may cause your baby to be at an increased risk of having a heart problem (cardiac malformations) at birth.</item>
                           <item>Taking paroxetine during your third trimester of pregnancy may cause your baby to have breathing, temperature, and feeding problems, low muscle tone, and irritability after birth and may cause your baby to be at an increased risk of a serious lung problem at birth. Talk to your healthcare provider about the risk to your unborn baby if you take paroxetine during pregnancy.</item>
                           <item>Tell your healthcare provider right away if you become pregnant or think you are pregnant during treatment with paroxetine tablets.</item>
                           <item>There is a pregnancy registry for females who are exposed to paroxetine during pregnancy. The purpose of the registry is to collect information about the health of females exposed to paroxetine and their baby. If you become pregnant during treatment with paroxetine tablets talk to your healthcare provider about registering with the National Pregnancy Registry for Antidepressants at 1-866-961-2388 or visit online at https://womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/antidepressants/.</item>
                        </list>
                     </item>
                     <item>are breastfeeding or plan to breastfeed. Paroxetine passes into your breast milk. Talk to your healthcare provider about thebestwaytofeedyourbabyduringtreatmentwithparoxetine tablets.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Tellyourhealthcareprovideraboutallthemedicinesyoutake</content>,includingprescriptionandover-the-countermedicines,vitamins,andherbalsupplements.</paragraph>
                  <paragraph>Paroxetine tablets and some other medicines may affect each other causing possible serious side effects. Paroxetine tablets may affect the way othermedicineswork andothermedicines mayaffectthewayparoxetine tablets works.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Especiallytellyourhealthcareproviderifyoutake:</content>
                  </paragraph>
                  <list>
                     <item>medicinesusedtotreatmigraineheadachescalledtriptans</item>
                     <item>tricyclicantidepressants</item>
                     <item>lithium</item>
                     <item>tramadol, fentanyl, meperidine, methadone, or other opioids</item>
                     <item>tryptophan</item>
                     <item>buspirone</item>
                     <item>amphetamines</item>
                     <item>St. JohnsWort</item>
                     <item>medicinesthatcanaffectbloodclottingsuchasaspirin,nonsteroidalanti-inflammatorydrugs(NSAIDs),warfarin</item>
                     <item>diuretics</item>
                     <item>tamoxifen</item>
                     <item>medicines used to treat mood, anxiety, psychotic, or thought disorders, including selective serotonin reuptake (SSRIs)andserotoninnorepinephrinereuptake inhibitors (SNRIs)</item>
                  </list>
                  <paragraph>Ask your healthcare provider if you are not sure if you are taking any of these medicines. Your healthcare provider can tell youifitis safetotakeparoxetine tabletswithyourothermedicines.</paragraph>
                  <paragraph>Do not start or stop any other medicines during treatment with paroxetine tablets without talking to your healthcare provider first. Stoppingparoxetine tabletssuddenlymaycauseyoutohaveserioussideeffects.See,<content styleCode="bold">Whatarethepossiblesideeffectsofparoxetine tablets?</content>
                  </paragraph>
                  <paragraph>Know the medicines you take. Keep a list of them to show to your healthcare provider and pharmacist when you get a newmedicine.</paragraph>
                  <paragraph>
                     <content styleCode="bold">HowshouldItakeparoxetine tablets?</content>
                  </paragraph>
                  <list>
                     <item>Takeparoxetine tabletsexactlyasprescribed.Yourhealthcareprovidermayneedtochangethedoseofparoxetine tabletsuntilitistherightdoseforyou.</item>
                     <item>Takeparoxetine tablets1timeeachdayinthemorning.</item>
                     <item>Paroxetinetablets maybetakenwithorwithoutfood.</item>
                     <item>Ifyoutaketoomuchparoxetine tablets,callyourpoisoncontrolcenterat1-800-222-1222orgotothenearesthospitalemergencyroomrightaway.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Whatarepossiblesideeffectsofparoxetine tablets?</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Paroxetine tablets cancauseserioussideeffects,including:</content>
                  </paragraph>
                  <list>
                     <item>See,<content styleCode="bold">WhatisthemostimportantinformationIshouldknowaboutparoxetine tablets?</content>
                     </item>
                     <item>
                        <content styleCode="bold">Serotoninsyndrome.</content>Apotentiallylife-threateningproblemcalledserotoninsyndromecanhappenwhenyoutakeparoxetine tabletswith certain other medicines. See, Who should not take paroxetine tablets? <content styleCode="bold">Call your healthcare provider or go to the nearesthospitalemergencyroomrightaway</content>ifyouhaveanyofthefollowingsignsandsymptomsofserotoninsyndrome:<list>
                           <item>agitation</item>
                           <item>seeingorhearingthingsthatarenotreal(hallucinations)</item>
                           <item>confusion</item>
                           <item>coma</item>
                           <item>fastheartbeat</item>
                           <item>changesinbloodpressure</item>
                           <item>dizziness</item>
                           <item>sweating</item>
                           <item>flushing</item>
                           <item>highbodytemperature (hyperthermia)</item>
                           <item>shaking(tremors),stiff muscles, ormuscle twitching</item>
                           <item>lossofcoordination</item>
                           <item>seizures</item>
                           <item>nausea,vomiting,diarrhea</item>
                        </list>
                     </item>
                  </list>
                  <list>
                     <item>
                        <content styleCode="bold">Eye problems (angle-closure glaucoma). </content>Paroxetine tablets may cause a type of eye problem called angle-closure glaucoma inpeople with certain other eye conditions. You may want to undergo an eye examination to see if you are at risk and receivepreventative treatment if you are. Call your healthcare provider if you have eye pain, changes in your vision, or swelling orrednessin or around the eye<content styleCode="bold">.</content>
                     </item>
                     <item>
                        <content styleCode="bold">Medicine interactions. </content>Taking paroxetine tablets with certain other medicines including thioridazine and pimozide may increase theriskof developinga seriousheart problemcalled QT prolongation<content styleCode="bold">.</content>
                     </item>
                     <item>
                        <content styleCode="bold">Seizures(convulsions).</content>
                     </item>
                     <item>
                        <content styleCode="bold">Manicepisodes.</content>Manicepisodesmayhappeninpeoplewithbipolardisorderwhotakeparoxetine tablets.Symptomsmayinclude:<list>
                           <item>greatlyincreasedenergy</item>
                           <item>severeproblemssleeping</item>
                           <item>racingthoughts</item>
                           <item>recklessbehavior</item>
                           <item>unusuallygrandideas </item>
                           <item>excessivehappinessorirritability</item>
                           <item>talkingmoreorfasterthanusual</item>
                        </list>
                     </item>
                  </list>
                  <list>
                     <item>
                        <content styleCode="bold">Discontinuation syndrome. </content>Suddenly stopping paroxetine tablets may cause you to have serious side effects. Your healthcareprovidermaywanttodecreaseyourdoseslowly.Symptomsmayinclude:<list>
                           <item>nausea</item>
                           <item>sweating</item>
                           <item>changesinyourmood</item>
                           <item>irritabilityandagitation</item>
                           <item>dizziness</item>
                           <item>electricshockfeeling(paresthesia)</item>
                           <item>tremor</item>
                           <item>anxiety</item>
                           <item>confusion</item>
                           <item>headache</item>
                           <item>tiredness</item>
                           <item>problems sleeping</item>
                           <item>hypomania</item>
                           <item>ringinginyourears(tinnitus)</item>
                           <item>seizures</item>
                        </list>
                     </item>
                  </list>
                  <list>
                     <item>
                        <content styleCode="bold">Low sodium levels in your blood (hyponatremia). </content>Low sodium levels in your blood that may be serious and may causedeath, can happen during treatment with paroxetine tablets. Elderly people and people who take certain medicines may be at agreaterriskfordevelopinglowsodiumlevelsinyourblood.Signsandsymptomsmayinclude:<list>
                           <item>headache</item>
                           <item>difficultyconcentrating</item>
                           <item>memorychanges</item>
                           <item>confusion</item>
                           <item>weaknessandunsteadinessonyourfeet which can lead tofalls</item>
                        </list>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Inmoresevereormoresuddencases,signsandsymptomsinclude:</content>
                  </paragraph>
                  <list>
                     <item>
                        <list>
                           <item>seeingorhearingthingsthatare notreal(hallucinations)</item>
                           <item>fainting</item>
                           <item>seizures</item>
                           <item>coma</item>
                           <item>stoppingbreathing(respiratoryarrest)</item>
                        </list>
                     </item>
                  </list>
                  <list>
                     <item>
                        <content styleCode="bold">Abnormal bleeding. </content>Taking paroxetine tablets with aspirin, NSAIDs, or blood thinners may increase this risk. Tell your healthcareprovideraboutanyunusualbleedingorbruising.</item>
                     <item>
                        <content styleCode="bold">Bonefractures.</content>
                     </item>
                     <item>
                        <content styleCode="bold">Sexual problems (dysfunction). </content>Taking selective serotonin reuptake inhibitors (SSRIs), including paroxetine tablets, may cause sexual problems. <br/>
                        <br/> Symptoms in males may include:<list>
                           <item>Delayed ejaculation or inability to have an ejaculation </item>
                           <item> Decreased sex drive  </item>
                           <item>Problems getting or keeping an erection</item>
                        </list>
                        <br/> Symptoms in females may include:<list>
                           <item>Decreased sex drive </item>
                           <item> Delayed orgasm or inability to have an orgasm <paragraph/>
                              <br/>
                           </item>
                        </list>
                        <paragraph>Talk to your healthcare provider if you develop any changes in your sexual function or if you have any questions or concerns about sexual problems during treatment with paroxetine. There may be treatments your healthcare provider can suggest.</paragraph>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Themostcommonsideeffectsofparoxetine tabletsinclude:</content>
                  </paragraph>
                  <list>
                     <item>maleandfemalesexualfunctionproblems </item>
                     <item>weakness (asthenia)</item>
                     <item>constipation</item>
                     <item> decreasedappetite</item>
                     <item>diarrhea</item>
                     <item> dizziness</item>
                     <item>drymouth </item>
                     <item>infection</item>
                     <item>problemssleeping</item>
                     <item> nausea</item>
                     <item>nervousness </item>
                     <item> sleepiness</item>
                     <item>sweating </item>
                     <item> shaking(tremor)</item>
                     <item>yawning</item>
                  </list>
                  <paragraph>Thesearenotallthepossiblesideeffectsofparoxetine tablets.</paragraph>
                  <paragraph>Callyourdoctorformedicaladviceaboutsideeffects.YoumayreportsideeffectstoFDAat1-800-FDA-1088.</paragraph>
                  <paragraph>
                     <content styleCode="bold">How shouldIstoreparoxetine tablets?</content>
                  </paragraph>
                  <list>
                     <item>Storeparoxetine tabletsat68F to 77F (20C to 25C).</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Keepparoxetineandallmedicinesoutofthereachofchildren.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Generalinformationaboutthesafeandeffectiveuseofparoxetine tablets.</content>
                  </paragraph>
                  <paragraph>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not take paroxetine tablets for acondition for which it was not prescribed. Do not give paroxetine tablets to other people, even if they have the same symptoms that youhave. It may harm them. You may ask your healthcare provider or pharmacist for information about paroxetine tablets that is written forhealthcareprofessionals.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Whataretheingredients inParoxetine Tablets?</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Active ingredient: </content>paroxetine hydrochloride</paragraph>
                  <paragraph>
                     <content styleCode="bold">Inactiveingredients:</content>
                  </paragraph>
                  <paragraph>anhydrous lactose, hydroxypropyl cellulose, hypromellose, magnesium stearate, polyethylene glycol, sodium starch glycolate and titanium dioxide.</paragraph>
                  <paragraph>
                     <content styleCode="bold">APOTEX INC.</content>
                     <content styleCode="bold"/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">PAROXETINE TABLETS, USP</content>
                     <content styleCode="bold"/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">10 mg, 20 mg, 30 mg and 40 mg</content>
                  </paragraph>
                  <table frame="void" rules="none">
                     <tbody>
                        <tr>
                           <td>
                              <content styleCode="bold">Manufactured by: </content>
                           </td>
                           <td>
                              <content styleCode="bold">Manufactured for:</content>
                           </td>
                        </tr>
                        <tr>
                           <td>Apotex Inc. </td>
                           <td>Apotex Corp. </td>
                        </tr>
                        <tr>
                           <td>Toronto, Ontario </td>
                           <td>Weston, Florida </td>
                        </tr>
                        <tr>
                           <td>Canada M9L 1T9 </td>
                           <td>USA 33326 </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>Revised: January 2025</paragraph>
                  <paragraph>Revision: 18</paragraph>
               </text>
               <effectiveTime value="20250103"/>
            </section>
         </component>
         <component>
            <section ID="_6b71486c-9bdf-1862-6ef3-e54e14b3cb1d">
               <id root="f7fb758f-11bc-2a79-d5ad-e155da6d572f"/>
               <code code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL" codeSystem="2.16.840.1.113883.6.1"/>
               <title>PRINCIPAL DISPLAY PANEL - 10 mg BOTTLE LABEL</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">APOTEX CORP. </content>NDC 60505-0097-1 </paragraph>
                  <paragraph>
                     <content styleCode="bold">PAROXETINE TABLETS, USP </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">10 mg </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold"/>30 Tablets</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM609920840716"/></paragraph>
                  <paragraph/>
               </text>
               <effectiveTime value="20240927"/>
            </section>
         </component>
         <component>
            <section ID="_ca7a314a-2449-c1a4-f40b-d8ee588966f0">
               <id root="c0d6d6b0-2427-c595-aeb4-114154f25185"/>
               <code code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL" codeSystem="2.16.840.1.113883.6.1"/>
               <title>PRINCIPAL DISPLAY PANEL - 20 mg BOTTLE LABEL</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">APOTEX CORP.</content> NDC 60505-0083-1</paragraph>
                  <paragraph>
                     <content styleCode="bold">PAROXETINE TABLETS, USP</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">20 mg</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx</content>
                  </paragraph>
                  <paragraph>30 Tablets</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM69655499239"/>
                  </paragraph>
               </text>
               <effectiveTime value="20240927"/>
            </section>
         </component>
         <component>
            <section ID="_ed080c1d-3e78-dc06-690c-5088c20460bd">
               <id root="e866e971-7ea4-a208-5cdd-f60f25e40183"/>
               <code code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL" codeSystem="2.16.840.1.113883.6.1"/>
               <title>PRINCIPAL DISPLAY PANEL - 30 mg BOTTLE LABEL</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">APOTEX CORP.</content> NDC 60505-0084-1</paragraph>
                  <paragraph>
                     <content styleCode="bold">PAROXETINE TABLETS, USP</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">30 mg</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx</content>
                  </paragraph>
                  <paragraph>30 Tablets</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM206243356011"/>
                  </paragraph>
                  <paragraph/>
               </text>
               <effectiveTime value="20240927"/>
            </section>
         </component>
         <component>
            <section ID="_46fdd3f1-66db-bc67-75b0-11d7ef4eaec7">
               <id root="b64643cd-29cf-5727-251a-718b2954d59e"/>
               <code code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL" codeSystem="2.16.840.1.113883.6.1"/>
               <title>PRINCIPAL DISPLAY PANEL - 40 mg BOTTLE LABEL</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">APOTEX CORP.</content> NDC 60505-0101-1</paragraph>
                  <paragraph>
                     <content styleCode="bold">PAROXETINE TABLETS, USP</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">40 mg</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx</content>
                  </paragraph>
                  <paragraph>30 Tablets</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM460627999389"/>
                  </paragraph>
               </text>
               <effectiveTime value="20240927"/>
            </section>
         </component>
      </structuredBody>
   </component>
</document>